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Summary 
New effective experimental techniques in medicinal chemistry and pharmacology 
have resulted in a vast increase in the number of pharmacologically interesting 
compounds. However, the possibility of producing drug candidates with optimal 
biopharmaceutical and pharmacokinetic properties is still improvable. A large fraction 
of typical drug candidates is poorly soluble in water, which results in low drug 
concentrations in gastrointestinal fluids and related acceptable low drug absorption. 
Therefore, gaining knowledge to improve the solubility of compounds is an 
indispensable requirement for developing compounds with drug-like properties. 
The main objective of this thesis was to investigate whether computer-based models 
derived from calculated molecular descriptors and structural fragments can be used 
to predict aqueous solubility for drug-like compounds with similar structures. For this 
purpose, both experimental and computational studies were performed. In the 
experimental work, a novel crystallization method for weak acids and bases was 
developed and applied for European patent. The obtained crystalline materials could 
be used for solubility measurements. A novel recognition method was developed to 
evaluate the tendency of compounds to form amorphous forms. This method could 
be used to ensure that only solubilities of crystalline materials were collected for the 
development of solubility prediction. In the development of improved in silico 
solubility models, lipophilicity was confirmed as the major driving factor and crystal 
information related descriptors as the second important factor for solubility. Reasons 
for the limited precision of commercial solubility prediction tools were identified. A 
general solubility model of high accuracy was obtained for drug-like compounds in 
congeneric series when lipophilicity was used as descriptor in combination with the 
structural fragments. Rules were derived from the prediction models of solubility 
which could be used by chemists or interested scientists as a rough guideline on the 
contribution of structural fragments on solubility: Aliphatic and polar fragments with 
high dipole moments are always considered as solubility enhancing. Strong acids 
and bases usually have lower intrinsic solubility than neutral ones. In summary, an 
improved solubility prediction method for congeneric series was developed using 
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high quality solubility results of drugs and drug precursors as input parameter. The 
derived model tried to overcome difficulties of commercially available prediction tools 
for solubility by focusing on structurally related series and showed higher predictive 
power for drug-like compounds in comparison to commercially available tools. Parts 
of the results of this work were protected by a patent application1, which was filed by 
F. Hoffmann-La Roche Ltd on August 30, 2005. 
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1 INTRODUCTION 
The therapeutic effect of a drug is based on the interaction between the drug and its 
specific receptor. Its strength and duration depend on the concentration of the drug 
near the receptor and the stability of the drug binding to the receptor. In order to 
reach the necessary concentration at the receptor site, the drug must be dissolved in 
the gastrointestinal (GI) tract at first and traverse several membrane barriers. In other 
words, the drug must be sensibly absorbed at first. Therefore, a good absorption is 
one precondition for high drug concentrations in the biophase. (Figure 1) 
 
Figure 1:  The influence of the absorption on the drug therapeutic effect2. 
Gastrointestinal absorption is dominated by passive uptake in the jejunum and ileum 
because of their high surface area. The majority of orally administered drugs are 
absorbed via the passive transcellular route3, so that in most situations, the intestinal 
absorption can be simplified as a passive diffusion process of a solute through the 
membrane. Such a simplified transport model can be described with Fick’s first law, 
in which the flux equation reduces to a product of permeability and solubility, when 
certain assumptions are made. In case of an ionizable molecule, the permeation by 
passive diffusion can only be very efficient, when the molecule is in its uncharged 
form at the membrane surface4. The amount of the uncharged form at a given pH 
depends on several important factors, such as pH, binding to indigenous carriers 
(proteins and bile acids), self-binding (aggregate or micelle formation), and solubility 
Introduction 
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(a solid-state form of self-binding)4. Thus, low aqueous solubility is usually related to 
low drug concentrations in gastrointestinal fluids, which can lead to impaired drug 
absorption. Therefore, gaining knowledge in improvement of solubility is a key 
prerequisite for successful development of drugs.  
Computational models for the prediction of aqueous solubility from electrotopology, 
molecular surface areas, lipophilicity, and hydrophilic measures have been devised, 
and several of these show impressive statistics5-10. However, all tools either 
commercially available or published by academia are usually restricted to deal with 
non drug-like molecules due to the limited number of published solubility data of 
drug-like compounds. Thus, developing a structurally based solubility prediction tool 
with high predictive power is an absolute necessity to give medicinal chemists 
constructive feedback on how to design better drug-like compounds with improved 
solubility. 
The main objective of this thesis was to investigate whether computer-based models 
derived from calculated molecular descriptors and structural fragments can be used 
to predict aqueous solubility for drug-like compounds with similar structures. For this 
purpose, both experimental and computational studies were performed. One 
objective in the experimental work was directed to the development of a novel 
crystallization method for weak acids and bases. Thus, crystalline material could be 
obtained for solubility measurements. Another objective in the experimental work was 
to develop a novel method to evaluate the tendency of compounds to form 
amorphous materials. This method could be used to ensure that only solubilities of 
crystalline materials were collected for the development of solubility prediction. The 
goal in the computational work was to find suitable descriptors for solubility prediction 
of drug-like compounds in congeneric series. The influence of crystal lattice on 
solubility was evaluated using compounds with information related to solid state, e.g. 
with known crystal structure or melting point. One of the obtained models was 
modified and improved using an extended dataset to predict the solubility of drug-like 
compounds in congeneric series. As a result of the improved prediction tool, 
structurally based solubility rules were derived, which can be the basis for the 
guidance of decision processes in the synthesis of more soluble drug-like candidates. 
  
 
 
 
Experimental Part 
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2 CRYSTALLIZATION 
2.1 Introduction 
Crystallization is an important purification and separation technique in a variety of 
commercial processes, as for example biotechnology, mineral processing, waste 
treatment, energy storage, production of new materials and electronic chemicals11. 
Crystallization can occur in solution, from vapor or from melt. Most processes in the 
chemical industries use crystallization from solution. The starting point for 
crystallization is the creation of a saturated solution. However, formation of a 
saturated solution is often a time-consuming process. Usually, it takes days until the 
equilibrium between the compound’s soluble and insoluble forms has been reached. 
Hence, the most currently known methods use a supersaturated solution, instead of 
a saturated one, as the starting point for the crystallization. In such cases, it is 
important to know the level of supersaturation, since supersaturation appropriate for 
crystallization varies from compound to compound. In general, with decreasing level 
of supersaturation, the crystal growth becomes slower and the crystal quality 
improves12. 
Crystallization using pH variation is a well-known method for proteins13-18, but rarely 
for drug molecules. Among the few publications found to use pH variation for drug 
crystallization, nicotinic acid was an example. Wang19 tried to obtain highly 
supersaturated solution of nicotinic acid by adding hydrochloride acid to an aqueous 
sodium nicotinate solution, which was then used as the starting point for the 
crystallization of nicotinic acid. Controlled batch crystallization by pH variation was 
another example developed by Zhu20. According to Zhu20, crystallization was 
initialized using a short pulse of supersaturation. pH was modified, during the whole 
crystallization process, in order to maintain a constant level of supersaturation. 
Furthermore, Zhu20 tried to raise the level of supersaturation to the highest 
concentration, in order to shorten the operation time. However, supersaturation could 
also be a risk for the formation of amorphous materials and the occurrence of crystal 
defects21. An alternative method is using a saturated solution. However, up to now, 
there is no scientific-based method available to identify the condition of formation of 
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saturated solution. Thus crystallization via saturated solutions is considered as 
impracticable for commercial purposes. 
This study closes the aforementioned gap in knowledge and application of saturated 
solution. For the first time, the invented new crystallization method successfully 
enables the generation of saturated solutions using pH-variations. Fine granular pH 
variations are applied to obtain the saturated solution. Crystallization process can be 
smoothly initialized and controlled, a key prerequisite for further optimization and 
application in a productive commercial environment. The breakthrough advantages of 
the new method are summarized as following: 
· Avoidance of buffer systems in the crystallization of compounds. 
· Improved control of crystal growth due to the use of the saturated solution. 
· Reduction of the possibility to obtain non-crystalline (amorphous) materials. 
2.2 Materials and methods 
2.2.1 Materials 
Diclofenac, famotidine, flurbiprofen, furosemide, hydrochlorothiazide, ketoprofen, 
propranolol, quinine were commercial compounds used for crystallization. 
Cyclopenthiazide and codeine are compounds with known polymorphic forms. 
Additionally, an internal compound with known polymorphs was included in the study. 
Their solubilities were determined via a potentiometric method. Crystalline materials 
of all compounds were successfully obtained using the invented new crystallization 
method. 
The pSol22 instrument usually foreseen for the potentiometric solubility 
measurements was used here to study crystallization processes. The pH-solubility 
profile obtained via pSol22 delivered a plot of pH against solubility, which was the key 
procedure for planning the crystallization experiments. 
Crystallization 
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2.2.2 Methods 
2.2.2.1 pKa assays applied 
A potentiometric titration method was used for the pKa determination of UV inactive 
compounds via the GLpKa23 equipment and a photometric method for UV active 
compounds via the Profiler SGA24 equipment. The methods are described in detail, in 
order to explain potential restrictions. 
2.2.2.1.1 Potentiometric Determination 
Usually, a blank titration is performed at the beginning of the measurement to 
calibrate the electrode. Afterwards, precisely known volumes of a standardized 
strong acid or base are added to a vigorously-stirred solution of a protogenic 
substance, while the pH is continuously measured with a  pH-electrode. The results 
of an experiment deliver two potentiometric titration curves, one with and one without 
sample as shown in Figure 2a4. 
Crystallization 
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a) 
 
b) 
 
c) 
 
d) 
Figure 2:  Four step construction of the Bjerrum difference plot for a molecule with three pKa values, 
whose constants are observed in the simple titration curve4. 
The potentiometric titration curve depicts the measured pH against titrant volume 
added. The shape can give information on the amount of substance present and its 
characteristic acid-base ionization properties. To reveal overlapping pKas, it is 
necessary to transform the titration curves into Bjerrum plots. Such a plot can be 
obtained by subtracting a titration curve containing no sample, “blank” titration, (left 
curve in Figure 2a), from a titration curve with sample, (right curve in Figure 2a), at 
fixed pH values. The difference between the total and the free concentrations is 
equal to the concentration of the bound hydrogen ions. The latter concentration 
divided by that of the sample gives the average number of bound hydrogen atoms 
per molecule of substances, Hn . The Bjerrum curve is a plot of Hn  vs. pcH. It reveals 
all the pKas as pcH values at half-integral Hn . 
Crystallization 
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2.2.2.1.2 Spectrophotometric determination of ionization constants 
The spectrophotometric method is based on the multiwavelength spectrophotometric 
approach from Tam and coworkers25. A UV light source, a fiber optic dip probe and a 
diode array detector are used to monitor the spectral changes that arise in the course 
of pH-metric titration of an ionizable compound. At the end of the measurement, TFA 
(target factor analysis)25 is used to calculate pKa values from the multi-wavelength 
spectrophotometric absorption titration data. 
2.2.2.2 Solubility assay applied 
2.2.2.2.1 Equilibrium solubility measurement by shake flask 
The measurement requires different diluted DMSO stock solutions for the calibration 
and a saturated buffer solution. A saturated buffer solution is obtained by adding a 
compound to a standard buffer solution until saturation occurs, indicated by 
undissolved excess of the compound. The thermostated saturated solution is shaken 
until equilibration between the solution and the solid phase is established. After 
micro-filtration or centrifugation, the concentration of the substance in the 
supernatant solution is determined using HPLC, usually via UV detection. (Figure 3) 
Crystallization 
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Figure 3:  The principal steps of an equilibrium solubility measurement26. 
 
  
In order to evaluate the experimental error of the Shake-Flask measurements, solubility of 6 drugs were measured five times. 
(Table 1). 
Exp1 Exp2 Exp3 Exp4 
Name ApKa1 BpKa1 BpKa2 MW S 
(µg/mL) 
log1/S  pH 
S 
(µg/mL) 
log1/S  pH 
S 
(µg/mL) 
log1/S  pH 
S 
(µg/mL) 
log1/S  pH 
log1/S 
average 
SE 
Mefenamic acid 4.2 0 0 241 11.42 4.32 6.5 2.78 4.94 6.5 3.95 4.79 6.5 5.2 4.67 6.5 4.68 0.19 
Flurbiprofen 4.03 0 0 244 2050.25 2.08 6.3 1128.56 2.33 6.3 1387.95 2.25 6.3 1442.54 2.23 6.3 2.22 0.07 
Astemizole 0 9.93 8.87 458 3.19 5.16 6.5 11.28 4.61 6.5 19.90 4.36 6.5 12.44 4.57 6.5 4.67 0.24 
Terfenadine 0 9.53 0 471 2.48 5.28 6.7 5.41 4.94 6.6 11.06 4.63 6.5 7.81 4.78 6.6 4.91 0.20 
Warfarin 0 0 0 308 157.91 3.29 6.5   6.5 129.24 3.38 6.4 123.79 3.40 6.5 3.35 0.04 
Iopanoic acid 4.5 0 0 570 38.02 4.18 6.5 15.63 4.56 6.5 23.39 4.39 6.5 19.50 4.47 6.5 4.40 0.12 
Table 1:  Equilibrium solubility measurements of 6 drugs, which are acids, bases and neutral compounds in the solubility range from low to high. 
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The compounds included acids, bases and neutral ones with a solubility range from 
low to high. The experimental standard error was calculated with Eq. 1 for each 
compound. 
 
n
SSABS
SE
n
i
avgnå -
= =0
/1log/1log
 Eq. 1 
The average standard error for the performed measurements was ±0.143 for the 
analyzed data set. 
2.2.2.2.2 Potentiometric solubility assay 
The potentiometric solubility assay was first described by Avdeef22. The 
measurement via this method requires an ionizable compound as reactant and a 
strong acid or a strong base as titrant. A blank titration is performed at the beginning 
of the measurement, similar to the procedure described for the determination of 
ionization constants. Afterwards, a certain amount of compound is placed in a 
reaction beaker and dissolved in a given volume of solvent. A titration is then 
performed in the direction of complete dissolution. During the measurement, the pH 
value is continually determined via a pH electrode. Similar to the potentiometric pKa 
assay, two potentiometric titration curves are obtained, and the corresponding 
Bjerrum plot is derived. Thus, the value of apparent pKa, (pKaApp), can be determined 
at the half-integral Hn  positions of Bjerrum plot. In case of weak acid, the apparent 
ionization constant, KaApp, is defined as Eq. 222.  
 
[ ][ ]
[ ] [ ]( )
[ ]
[ ] [ ]( )sa
s
APP
a
HAHA
HA
K
HAHA
HA
K
+
=
+
=
+-
 Eq. 2 
[HA] is the concentration of the molecule HA in the solution. [HA](s) is the moles of the 
molecule HA, which precipitated per liter of aqueous solution. 
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At the half-integral Hn  positions of Bjerrum plot, half of the total amount of the 
substance is protonated, thus, the concentration of the free acid, HA, equals that of 
the conjugate base, A-. (Eq. 3) 
 [ ] [ ] [ ]
2
C
AHAHA s ==+
-  Eq. 3 
[A-] is the concentration of the conjugate base, A- in the solution. C is the total 
amount of substance in the solution and solid phase. 
Combining Eq. 2 and Eq. 3 together, the value of intrinsic solubility can then be 
deduced from the Eq. 4 using the experimentally determined pKa value and the 
sample concentration, C, as input parameters. 
 [ ] aAppa pKpK
C
HAS +-==
2
logloglog 0  Eq. 4 
2.2.2.3 Description of the crystallization assay 
Crystallization is considered as a kinetic process and illustrated with the help of the 
pH-solubility profile using a weak base as an example. (Figure 4) 
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Figure 4:  Solubility-pH profile of a weak base. B is the soluble form of the weak base. B(s) is the solid 
form of the weak base. BH+ is the charged form of the weak base. 
In region A, the compound is in equilibrium and solubility stays constant. Eq. 5 
describes the equilibrium in region A. 
 BH+ B B(s)  Eq. 5 
In region B, solubility rises with the increasing amount of BH+, when pH changes 
from high to low. This means, when a basic compound is titrated from its insoluble to 
its soluble form, an increasing amount of uncharged precipitate B(s) will go into 
solution with increasing hydrogen concentration [H+]. This will continue, until point 2 
is reached. At point 2, a “perfect” buffer system4 exists. The simultaneous presence 
of solid free base and its solid conjugate acid force the pH and solubility to be 
constant, as long as the two interconverting solids are present. This special pH point 
has been designated as the Gibbs’ pKa (pKaGIBBS)4. The equilibrium equation 
associated with this phenomenon is Eq. 6. 
 BH+(s) B(s) + H+  Eq. 6 
 
{ }{ }
{ }+
+
=
)(
)(
s
sGIBBS
a BH
BH
K  Eq. 7 
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The solubility at point 2 is S = S0 + S i. The constants S0 and Si are intrinsic and salt 
solubility4. 
From point 2 on, (in region C), BH+(s) will be only won in credit of B in the  solution and 
solubility decreases with ++ ®+ )(sBHHB , until region D is reached. In region D, no 
more B will be changed into BH+(s) and the minimum of [B] is achieved. The 
equilibrium existing there is described by Eq. 8: 
 BH+(s) BH+ B + H+  Eq. 8 
However, during the potentiometric titration, one is not very frequently able to 
observe the phenomenon of the “perfect” buffer system, because in order to get a 
good titration, it is always recommended to use a small amount of compound. And 
this leads to the situation, that the whole amount of compound is dissolved before the 
maximal concentration of salt in solution ([BH+]max at point 2) is reached. The point 
where the whole amount of compound dissolved in the solution is signified as 2’ in 
Figure 5; at this point, the compound reaches its total solubility. The total solubility 
does not change with pH and is signified in Figure 5 by the blue dashed line. 
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Figure 5:  Solubility-pH profile of a weak base. B is the soluble form of weak base. B(s) is the solid 
form of weak base. BH+ is the charged form of weak base. 
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According to the new crystallization method, crystals can be easily obtained, when 
the direction of titration described above is reversed. In the case of a weakly basic 
compound B, one starts with an unsaturated solution of the compound at a low initial 
pH-value as illustrated in Figure 5 by means of point 3’, which can be varied by the 
amount of the compound used. Subsequently, the pH value is gradually increased by 
adding a strong basic titrant to the solution. This leads to an increasing deprotonation 
of BH+ to B, but initially, there is no precipitation of solid phase. By reaching point 2’, 
the titration is stopped. At this target point 2’, the concentration of the uncharged form 
has reached its maximal value [B]max, which is equal to the intrinsic solubility S0. 
Therefore, a saturated solution of the compound of interest has been reached that 
may serve to carry out a crystallization under substantially saturated conditions. 
Hence, at the point 2’, the probability for the formation of the neutral form is at its 
maximum. 
The point of saturation can be precisely identified via the pH-solubility profile and can 
be easily reached using pH-titration. Therefore, generation of saturated solution is no 
more a time-consuming process since the advent of the invented new crystallization 
method. Furthermore, the newly developed method uses saturated solution instead 
of highly supersaturated solution as the starting point for the crystallization. Hence, 
the shortcoming of the currently known method can be avoided. The control of the 
crystal growth can be improved and the possibility to obtain non-crystalline form can 
be reduced using the new crystallization method. However, due to practical 
limitations, it may be difficult to reach the target point 2’ very precisely. If too much 
base is added, the pH-value goes beyond the targeted pH-value corresponding to 
point 2’ and a supersaturated solution is formed. Therefore, the titration is usually 
stopped at a point very close to the solubility-pH profile that corresponds to a slightly 
unsaturated solution. By keeping the solution at defined conditions allowing 
controlled slow solvent evaporation, the concentration of the solution will slowly 
increase so that the saturated state is reached. In order to obtain good crystallization 
results and reduce the risk of forming amorphous solid materials, an improved 
system might be of advantage for monitoring the concentration of the uncharged form 
and regulating the pH-value so that the concentration of the uncharged form is kept 
within a predefined tolerance range above the intrinsic solubility. Alternatively, the 
Crystallization 
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improved system may monitor the total concentration of the compound and regulate 
the pH-value so that the total concentration is kept within a predefined tolerance 
range above the predetermined total solubility profile.  
2.3 Results and discussion 
2.3.1 Crystallization of known drugs 
The known drugs famotidine, diclofenac, flurbiprofen, furosemide, 
hydrochlorothiazide, ketoprofen, propranolol and quinine were used to verify the 
readiness and applicability of the new crystallization method. Crystals with high 
quality were obtained and their microscopic pictures are depicted in Figure 6. 
Famotidine Diclofenac 
Flurbiprofen Furosemide 
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Hydrochlorothiazide  Ketoprofen  
Propranolol  Quinine  
Figure 6:  Crystals of diclofenac, famotidine, flurbiprofen, furosemide, hydrochlorothiazide, 
ketoprofen, propranolol, and quinine obtained using the new crystallization method. 
2.3.2 Crystallization of internal development compounds 
The application of the newly developed crystallization method was further extended 
to several development compounds. Compound 1 is an internal compound with 
ability of forming amorphous and polymorphic forms. Its pKa, equilibrium and 
potentiometric results are summarized in Table 2. 
Equilibrium solubility pSol 
Name 
Polymorphic 
forms  ApKa1 BpKa1 
S 
(µg/mL) pH Solution 
S0 
(µg/mL) 
S0 
(µg/mL) 
compound 1 Mod C 7.62 4.01 43 9.6 
Boric 
acid/KCl-
NaOH 
pH=10 0.5 0.135  
Table 2:  Solubility measured using equilibrium and potentiometric methods. 
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Three polymorphic forms are known for compound 1. Among them, modification A is 
known to be the most stable form, which is formed via transition from modification B; 
modification B is an anhydrate and modification C is hydrate. The crystals obtained 
via the crystallization method had the form of yellow needles. (Figure 7) Through the 
comparison with the reference data, the obtained crystals were characterized by 
powder diffraction as modification C. (Figure 8 and Figure 9) 
 
Figure 7:  Crystals of compound 1. 
 
Figure 8:  Powder diffraction diagram of crystal forms (red and blue) of compound 1 obtained via 
crystallization method. The obtained crystals show the same diffraction pattern as crystals 
in modification C (green) in reference diagram. 
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Figure 9:  Powder diffraction diagram of three different crystal forms of compound 1. They are used 
as reference diagrams in order to identify the crystal form obtained via the new 
crystallization method. In the reference diagram the form A is colored in red, form B in blue 
and form C in green. 
The result of the crystallization of modification C confirmed the readiness of the new 
crystallization method. Since the method is based on titration in aqueous solution, 
hydrates are usually obtained. 
2.3.3 Crystallization of external polymorphs 
Pudipeddi27 has shown that in a data set of 72 compounds with different polymorphic 
forms, usually small differences in their solubilities were determined. The described 
differences in the solubilities were often in the range of the experimental error of the 
solubility measurements. Extensive literature searches were performed in order to 
identify compounds showing large differences in the measured solubilities of their 
polymorphic subtypes. Several interesting drugs could be found with much larger 
solubility differences. One of those examples is premafloxacin.28 There is a 30 fold 
solubility difference described between polymorphic form I and III of premafloxacin. 
The other examples are codeine29 and cyclopenthiazide30 with a 13 fold difference for 
codeine between hydrate and other crystal forms. A 4 fold difference was described 
between the polymorphic form II and III of cyclopenthiazide. 
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Except for premafloxacin, cyclopenthiazide and codeine were available for further 
characterization and application of the new crystallization method. 
The physicochemical properties of the three cyclopenthiazide polymorphic forms, 
according to Gerber30, are summarized in Table 3: 
Polymorph Melting point (°C) Solubility in water (µg/mL) 
I 239.33 34.7 
II 223.03 61.8 
III 187.87 and 233.48 17.15 
Table 3:  Physicochemical properties of diverse cyclopenthiazide polymorphic forms. 
After the crystallization, white needles were obtained (Figure 10) with a melting point 
of 233°C. No powder diffraction diagram was described for cyclopenthiazide by 
Gerber30. Therefore a direct comparison between obtained crystals and those 
described in the literature was not possible. Based on the similarity in melting points, 
it can be assumed that the obtained crystals belonged to the polymorphic form III, the 
most stable one with the lowest solubility. 
 
Figure 10:  Crystals of cyclopenthiazide. 
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El-Gindy29,31 described the solubility of three polymorphic forms of codeine, which are 
summarized in the Table 4. 
Polymorph Solubility in water (g/mL) 
I 8.103 
II 11.123 
III 80.431 
Table 4:  Solubility of diverse polymorphic forms of codeine. 
White needles were obtained by applying the new crystallization method. (Figure 11b) 
Its 3D structure was solved by single crystal X-ray analysis. (Figure 11a and c) 
Crystallization 
- 35 - 
O
N
+
OH
O
H
H
H
H
H2O
H2O
Cl-
 
a) 
 
b) 
 
c) 
Figure 11:  Codeine crystals obtained by the new method. a) 2D structure; b) microscopic photo; c) the 
3D structure identified by the single crystal X-ray analysis. 
Figure 11 shows, that instead of the free basic form, a chloride salt form of codeine 
with two water molecules in crystal packing was obtained. 
In this case, the formation of codeine salt solids shows the practical limitations of the 
newly developed crystallization method. As in chapter 2.2.2.3  described, the titration 
is stopped at a point very close to the pH-solubility profile which corresponds to a 
slightly unsaturated solution. During the slight evaporation process, the concentration 
of the solution increases, until the saturated state, resp. a point 2’ in the Figure 12 is 
reached. 
Crystallization 
- 36 - 
Region A
Region B
Region C
pKa
Region D
1
2
3
2‘
pH
S
o
lu
b
ili
ty
2‘
2‘
Lower tendency of 
forming salts!
S
o
lu
b
ili
ty
 
Figure 12:  Solubility-pH profile of a weak base. Reduction in concentration of a compound leads to 
lower tendency of forming salts. 
The point 2’ is considered as the starting point for the crystallization. Dependent on 
the concentration of the compound and the relative orientation of the point 2’, the 
concentration of counter ions can be high, which can influence the crystallization 
process and the obtained crystal form. When crystallization starts at point 2, then the 
crystallization process is a competition between charged and uncharged form. The 
charged salt solid has generally a stronger crystal lattice than the uncharged solid 
form, because of the strong ionic interactions between the cations and anions. Thus, 
the closer 2’ moves to the point 2, the higher the tendency of obtaining salt solid than 
the formation of uncharged materials. Therefore, in order to enhance the possibility of 
obtaining an uncharged form, a reduced concentration of the compound is 
recommended to be utilized for the crystallization, i.e. 2’ should be sufficiently kept 
away from 2. 
In conclusion, a new crystallization method has been developed for weak acidic and 
basic compounds. According to this method, one can rapidly proceed to a situation in 
which the solution is in a substantially saturated state, by gradually changing the pH-
value of the solution in a direction that leads to a decrease of said compound’s 
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solubility. In particular, one can avoid the drawbacks associated with crystallization 
from a supersaturated state, because crystallization is then carried out under the 
most desirable conditions, by maintaining the solution in a substantially saturated 
state. According to the described results, there is a high probability to get hydrates 
with low solubilities by the described method. However the example of codeine 
shows that further optimization of the method can probably improve the results. In all 
the eleven analyzed cases, crystals could be obtained easily via the pH-solubility 
profile using the sample concentration and experimental pKa as input parameters. 
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3 EVALUATION OF THE TENDENCY TO FORM 
AMORPHOUS MATERIAL 
3.1 Introduction 
Amorphous solids, or glasses, are phase intermediates between solids and liquids. 
The atoms in an amorphous solid are aligned in a rigid disordered structure, instead 
of a regular lattice like ordinary ("crystalline") solid. Various  degrees of disorder in the 
solid form result in inconsistent properties of amorphous solids in comparison to their 
cystalline counterparts. Additionally, the instability of amorphous solids may lead to 
crystallization after long time of storage. Therefore, it is often a significant risk for 
pharmaceutical industry to produce amorphous instead of crystalline solids for 
medicines. The following chapter investigates the tendency of compounds to form 
amorphous materials. The achieved results help to improve the design and 
production of pure and stable pharmaceuticals. 
The formation of amorphous solids is firstly dependent on the condition of crystal 
growth. For example, a crystal system can be driven by a high degree of 
supersaturation to an order-disorder transition, resulting in an amorphous solid32-35. 
Secondly, the formation of amorphous solids is compound-specific21. For example, 
relatively large molecules and molecules with a certain degree of rotational flexibility 
tend to form a disordered state even at mild crystallization conditions21. Therefore, 
being able to identify the degree of supersaturation, is helpful in reducing the 
possibility of obtaining amorphous materials and crystal defects. Hence, the first goal 
of this work was directed toward the evaluation of potential rules for the formation of 
amorphous materials. 
High Throughput (HT) solubility assay uses freeze-drying procedure to eliminate 
DMSO from the stock solution. Prepared solids can be used as basis for the solubility 
determination. Usually, the solubility results of equilibrium and HT-solubility assays 
are similar, but can be different in specific cases if the characteristics of the solid 
forms change during the evaporation process in HT-solubility measurements. 
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Therefore, the second direction of this work is researching potential differences in the 
results of equilibrium and HT-solubility measurements. 
3.2 Materials and methods 
3.2.1 Materials 
Bosentan, trazodone, glibenclamide, iodopanoic acid are commercial compounds 
used to test the working principle of the new evaluation method. 
The pSol22 equipment for the potentiometric solubility measurement was used here to 
evaluate the tendency for the formation of amorphous materials. The characteristics 
of pSol22 have already been described in chapter 2. 
pH-Solubility profile, Bjerrum plot and speciation profile are obtained by 
potentiometric solubility measurements. 
· The pH-solubility profile describes the plot of pH against solubility. 
· The Bjerrum plot depicts pH against Hn . Hn  is the average number of the 
bound hydrogen atoms per molecule of substance. Therefore, the Bjerrum plot 
reveals all pKas as pH values at half-integral Hn  positions.  
· The normalized speciation profile depicts pH against the normalized 
concentration of all compound species. 
The function of these three plots and the relationship between them is demonstrated 
using famotidine as an example. 
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Figure 13:  Famotidine titrated from its insoluble to soluble form. a) pH-solubility profile; b) Bjerrum 
plot; c) Speciation profile. The blue colored curve describes the titration in the absence of 
precipitate FaH. The blue colored curve describes the titration in the presence of 
precipitate FaH. The red points represent the collected experimental data. 
The pH-solubility profile of famotidine (Figure 13a) can be divided into four regions by 
three defined points, resp. point 1, 2’ and 3’, which can be retrieved via the speciation 
profile. (Figure 13c) In the speciation profile, famotidine exists in region A dominantly 
in its precipitated form, FaH(s), and the soluble form FaH; in region B, FaH(s), FaH and 
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its ionic form FaH2+; in region C, FaH and FaH2+ coexist; in region D, FaH2+ is the 
major component. 
In Figure 13b, the Bjerrum plot of famotidine is depicted. The blue colored curve is 
the reference curve and describes the titration in the absence of precipitate FaH. 
With the help of the reference curve, points 1 and 2’ in the solubility profile can be 
defined in Bjerrum plot, as well. When famotidine is titrated from its insoluble to 
soluble form, data are collected and represented as red points in Figure 13b. In case 
of missing supersaturation, experimental data collection runs along the red curve, 
which stays for the titration in the presence of precipitate. The red curve meets the 
reference curve at two different points. The first one is the same as point 1 in the 
solubility profile. It indicates the status of the minimal concentration of the charged 
form in solution. Continuing the titration to lower pH, the total concentration in 
solution increases. More and more uncharged precipitate FaH(s) is transformed to the 
charged form, FaH+, while the concentration of the uncharged form in the solution 
stays constant. Finally, the intersection of the titration and reference curve is reached. 
This intersection point is equal to point 2’ in the solubility profile. At this point, the 
uncharged precipitate FaH(s) has reached its minimum concentration and the whole 
amount of the compound is dissolved in the solution. From point 2’ to 3’, the charged 
form BH+ will only go into the solution at the expense of the dissolved uncharged 
form B, therefore, the solubility does not change with pH. 
3.2.2 Methods 
3.2.2.1 High Throughput solubility assay 
High Throughput (HT) solubility assays use the solvent evaporation process and in 
principle are modified Shake-Flask assays. Saturated buffer solutions are prepared 
by adding buffer to the solid materials which are obtained through freeze-drying to 
eliminate the DMSO from the stock solution. (Figure 14)  
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Figure 14:  The principal steps of a High Throughput solubility measurement26. 
3.2.2.2 Assay description for the evaluation of the tendency to form 
amorphous material 
The tendency to form amorphous forms is compound-specific21 and can be related to 
the occurrence of high degree of supersaturation, observed in crystallization 
experiments. The crystallization method described in chapter 2 is based on the 
titration of a compound from its soluble to its insoluble form. The reverse titration 
procedure described by Avdeef22 is used in the determination of intrinsic solubility. 
Hence, a compound can be titrated in both directions, resp. from soluble to insoluble 
or reverse. The obtained curves should usually be identical, but can be different in 
cases when compounds have the tendency to form highly supersaturated solutions. 
Therefore, comparing the curves obtained by reverse titration experiments allows to 
detect supersaturation effects and can give some insight into tendencies of 
compounds to form amorphous materials. 
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Famotidine has two pKa values, about 6.74 and 11.19. Two titrations were performed 
for famotidine. One was from its soluble to insoluble form and the other was from its 
insoluble to soluble form as depicted in Figure 15 by focusing on the basic pKa.  
Evaluation of the tendency to form amorphous material 
- 45 - 
N
S
N
NH2
NH2
S
NH
NH
S
NH2
O
O  
ApKa = 11.19 
BpKa = 6.74 
3
2
1
5       6        7       8       9       10     11
pH
nH
1
2’
2’’
 
a) 
2‘
1
nH
pH
3
2
1
4        5       6        7       8       9      10     11 
 
b) 
pH-solubility profile of famotidine titrated from its 
soluble to insoluble form
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
6500
7000
7500
0 1 2 3 4 5 6 7 8 9 10 11 12
pH
S
o
lu
b
ili
ty
 (
u
g
/m
L
)
Supersaturation
1
2’3’
2’’
Region A
Region B
Region CRegion D
S
o
lu
b
ili
ty
 (
u
g
/m
L
)
S
o
lu
b
ili
ty
 (
u
g
/m
L
)
S
o
lu
b
ili
ty
 (
u
g
/m
L
)
S
o
lu
b
ili
ty
 (
u
g
/m
L
)
 
c) 
pH-solubility profile of famotidine titrated from 
its insoluble to soluble form 
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
0 1 2 3 4 5 6 7 8 9 10 11 12
pH
S
o
lu
b
ili
ty
 (
u
g
/m
L
)
2’
1
3’
Region A
Region B
Region CRegion D
S
o
lu
b
ili
ty
 (
u
g
/m
L
)
S
o
lu
b
ili
ty
 (
u
g
/m
L
)
S
o
lu
b
ili
ty
 (
u
g
/m
L
)
 
d) 
Figure 15:  Bjerrum plot and pH-solubility profile of famotidine. The direction of titration is given by red 
arrow. The red curve in the Bjerrum plot is the calculated titration curve in the presence of 
precipitate, the blue curve is the calculated titration curve in the absence of precipitate and 
the unfilled circles are the experimental points registered during the titration. a) Bjerrum 
plot titrated from the soluble to insoluble form; b) Bjerrum plot titrated from the insoluble to 
soluble form; c) pH-solubility profile titrated from the soluble to insoluble form; d) pH-
solubility profile titrated from the insoluble to soluble form. 
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When famotidine was titrated from its soluble to insoluble form, the curve determined 
by the potentiometric method was not identical with the calculated Bjerrum curve 
from pH 6 to 6.5. The experimental data were following preferably the blue curve to 
some extend and jumped back to the red curve, when the precipitation started. 
Therefore, in this pH range, more famotidine was dissolved than expected and this 
phenomenon indicated the occurrence of supersaturation36. Hence, in this case, 
precipitation began not at point 2’, but at point 2’’. Furthermore, at point 2’’, where the 
precipitate appeared, the precipitation rate could be large which was one 
precondition for the generation of amorphous materials. Figure 15c shows the 
corresponding pH-solubility profile. The unusual curve form in region B was another 
indicator for the occurrence of supersaturation. 
Figure 15b and d show the Bjerrum plot and pH-solubility profile, when famotidine 
was titrated from its insoluble to soluble form. In this titration direction, the 
experimental data moved along the red curve and supersaturation did not occur. This 
was the appropriate direction to measure the intrinsic solubility. 
For the first time, this study demonstrated that potentiometric titration from reverse 
directions can be used to detect the occurrence of supersaturation and to evaluate 
the level of the supersaturation. Due to its easy and comfortable performance, this 
new method can be utilized in the early drug discovery phase as a quick recognition 
procedure to identify the tendency of compounds to form amorphous materials. The 
results of the new method may explain complicated, difficult-to-understand biological 
processes, e.g. high absorption caused by formation of supersaturation in the in vivo 
test. Furthermore, this finding can streamline formulation activities in the later drug 
development where information on supersaturation and relative probability for the 
formation of amorphous forms is mandatory. 
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3.3 Results and discussion 
Four drugs, bosentan, trazodone, glibenclamide and iodopanoic acid showed large 
differences in their equilibrium and HT solubility values. They were taken as 
examples to evaluate the working principle of the newly developed method. Bosentan 
has an acid pKa of 5.46, trazodone a basic pKa of 6.6, glibenclamide an acid pKa of 
4.5 and iopanoic acid an acid pKa of 4.5. 
3.3.1 Bosentan 
Bosentan is a drug identified with large differences in solubility results obtained using 
equilibrium and HT-solubility assays. The titration behavior of bosentan was 
investigated by bidirectional titration experiments as described. 
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Figure 16:  pH-solubility profile of bosentan. a) Profiles obtained by titration of bosentan from its 
insoluble to soluble form; b) profiles obtained by titration of bosentan from its soluble to 
insoluble form. 
The profiles obtained from titrations should be independent on the titration directions, 
in case when the compound does not form supersaturated solution. However, for 
bosentan, this was not the case. In comparison with the profiles obtained by titration 
from the insoluble to soluble form, the profiles obtained by reverse direction were not 
Evaluation of the tendency to form amorphous material 
- 49 - 
reproducible and were partly dependent on degrees of supersaturation. Furthermore, 
at the same pH value, the solubility value of bosentan obtained by titration from its 
insoluble to soluble form was much lower than from the reverse direction, which was 
a strong indication for supersaturation. 
The reverse titration results are helpful to explain the differences obtained by 
equilibrium and HT-solubility assays. (Table 5)  
Name Method pKa 
S 
(µg/mL) 
pH S0 (µg/mL) Back ground solution 
Titration 
direction 
Bosentan 
Equilibrium 
solubility 
5.46 14 6.6 0.946 50mM Phosphate pH=6.5  
Bosentan 
HT-
solubility 
5.46 1260 6.5 105.3 50mM Phosphate pH=6.5  
Bosentan pSol 5.46   0.942 0.15 N KCl 
Insoluble to 
soluble 
Bosentan pSol 5.46   48.5 – 116.6 0.15 N KCl 
Soluble to 
insoluble 
Table 5:  Equilibrium, High Throughput and potentiometric solubility measurements of bosentan. 
Table 5 shows that for bosentan, higher HT-solubility value in comparison to  
equilibrium solubility was obtained. In case of the HT-solubility assay, freeze-drying 
was used to eliminate DMSO from the stock solution. Thus, the amorphous form of 
bosentan could possibly be obtained because of its preference to form 
supersaturated solutions. This assumption was confirmed by the potentiometric 
results as well. Titrating bosentan from its soluble to insoluble form, higher solubility 
values were obtained than in reverse direction. Furthermore, the higher 
potentiometric result (S0 = 116.6) agreed with the higher HT-solubility value (S0 (HT-
solubility) = 105.3) and the lower potentiometric result (S0 = 0.942) with the lower 
equilibrium solubility value (S0 (equilibrium solubility) = 0.946). Therefore, differences in 
equilibrium and HT-solubility can be explained by analysis of different solid forms. 
Reverse potentiometric titrations can be used to estimate the tendency of 
compounds to form supersaturated solutions, which is one precondition for the 
formation of amorphous materials. 
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3.3.2 Trazodone 
Trazodone is another example showing a large deviation between its equilibrium and 
HT-solubility. Because the purchasable basic form of trazodone was only available 
as a methanol solution, the salt solid form, trazodone hydrochloride was used to 
study the behavior of trazodone in titration experiments.  
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Figure 17:  Bjerrum plot of trazodone. a) Titrated from insoluble to soluble form; b) titrated from soluble 
to insoluble form. 
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Name Method pKa 
S 
(µg/mL) 
pH S0 (µg/mL) Background solution 
Titration 
direction 
Trazodone 
Equilibrium 
solubility 
6.6 68 13 68 500mM KOH  
Trazodone 
HT-
solubility 
6.6 > 454 6.5 > 201 50mM Phosphate pH=6.5  
Trazodone pSol 6.6   105.1 0.15 N KCl 
Insoluble to 
soluble 
Trazodone pSol 6.6   453.7 0.15 N KCl 
Soluble to 
insoluble 
Table 6:  Equilibrium, High Throughput and potentiometric solubility measurement of trazodone. 
Similar amounts of trazodone HCl were taken for the titration in opposite directions. 
From soluble to insoluble form, the precipitation occurred at pH = 6, much later than 
in the reverse direction (pH = 4.5). Therefore, high supersaturation was assumed to 
occur in this direction, which was confirmed by the agreement between the solubility 
result obtained in this direction (S0 = 453.7 ug/mL) and the high HT-solubility value 
(S0 (HT-solubility) > 201 ug/mL). 
3.3.3 Glibenclamide and Iopanoic acid 
Glibenclamide and iopanoic acid are two compounds described by Hancock37 to 
show high solubility differences between amorphous and crystalline materials. (Table 
7)  
Compound Forms Solubility ratio Comments 
Glibenclamide Amorphous/crystal 14 23 °C, buffer (aq.) 
Iopanoic acid Amorphous/I-crystal 3.7 37°C, phosphate buffer (aq.) 
Table 7:  Experimental solubility ratios for glibenclamide and iopanoic acid37. 
Equilibrium, High Throughput and potentiometric solubility results of glibenclamide 
and iopanoic acid are summarized in Table 8.  
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Potentiometric method 
Equilibrium solubility HT-solubility 
From 
insoluble to 
soluble 
From soluble 
to insoluble Name ApKa 
S 
(µg/mL) 
pH 
S0 
(µg/mL) 
S 
(µg/mL) 
pH 
S0 
(µg/mL) 
S0 (µg/mL) S0 (µg/mL) 
Glibenclamide 4.5 0.33 6.5 0.003 52 6.5 0.515 0.009 0.046 
Iopanoic acid 4.5 38.02 6.5 0.377 213 6.5 2.11 0.405 6.2 
Table 8:  Equilibrium, High Throughput and potentiometric solubility of glibenclamide and iopanoic 
acid. 
Table 8 shows the amorphous formation tendencies of glibenclamide and iopanoic 
acid were confirmed, firstly by the different equilibrium and HT-solubility results; 
secondly by the different potentiometric results obtained using reverse titration 
experiments. 
3.4 Conclusion 
In conclusion, the crystallization procedure described in chapter 2 is based on the 
titration of a compound from its soluble to insoluble form. The often observed 
occurrence of high supersaturation in this direction can be assumed to be one 
precondition for the formation of amorphous materials. Thus, comparing the titration 
behavior of compounds from opposite directions is a new and easy procedure to 
evaluate the tendency for the formation of amorphous solids and one possibility to 
explain differences in the results of solubility experiments. Therefore, this work 
discovered a new procedure with the following advantages: 
· Quickly identifies the tendency of compounds to form amorphous materials. 
· Helps to improve the design and production of pure and stable 
pharmaceuticals. 
· Streamlines formulation activities in the later drug development where 
information on supersaturation and relative probability for the formation of 
amorphous forms is mandatory.  
· May explain complicated, difficult-to-understand biological processes, e.g. 
high absorption caused by formation of supersaturation in the in vivo test. 
  
 
 
 
Prediction Part 
 - 55 - 
4 AQUEOUS SOLUBILITY PREDICTION OF DRUG-LIKE 
COMPOUNDS 
4.1 Introduction 
The majority of prediction tools for solubility are generic tools. There is only a small 
number of tools dealing with congeneric series. Usually, all tools either commercially 
available or published by academia are restricted to deal with non drug-like 
molecules due to the limited number of published solubility data of drug-like 
compounds. The following short summary will give an overview on the data sets, 
descriptors and methods which have been used in the development of prediction 
tools for solubility in the past. The predictive power of commercially available tools 
was evaluated using a newly collected data set of drug-like compounds. Finally, a 
comparison of published and newly collected data sets was performed and the 
difference in the related data sets is described. 
4.1.1 Solubility prediction tools 
4.1.1.1 Data sets used in solubility prediction 
Usually, data sets from PHYSPROP database38-43, Huuskonen44, AQUASOL5,39,40,45 
are used in the parameterization of solubility prediction tools. A few groups38-42,46,47 
collected data sets from different literature sources9,48, with focus on solubility 
measured under identical experimental conditions. High quality measurement data 
have been used in the prediction tools developed by  McFarland10, Klamt49 and 
Bergström50. 
4.1.1.2 Methods and descriptors 
The principal computational approaches for solubility prediction can be grouped into 
two classes: 
· Multiple linear regression (MLR) based 
· Neural networks (NN) based 
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4.1.1.2.1 Multiple linear regression 
In multiple linear regression based approaches, the correlation between solubility (S) 
and its relevant descriptors is computed, according to the Eq. 9. 
 å +=
i
ii acaS 0log  Eq. 9 
where ci are values of different molecular descriptors i for the given molecule and ai 
are the corresponding coefficients determined by regression analysis, in order to 
maximize the correlation coefficient r2 between the measured and computed solubility 
results. 
When structural fragments are used as descriptors, the multiple linear regression 
method can be defined as a Group Contribution (GC) approach and a i are increments 
assigned to the number of occurrences ci of a structural fragment i in the molecule of 
interest.  
When structural properties are used as descriptors, the multiple linear regression 
method is named Property Contribution approach and ci are values of different 
molecular properties for the given structure. The properties used in multiple linear 
regressions can be divided into two classes: experimental and calculated. The 
experimental properties can be, for example, melting points, boiling points, and 
lipophilicity. Calculated properties usually used are molecular weight, solvent-
accessible surface area (SASA), counts of potential donor and acceptor hydrogen 
bonds (HBDN, HBAC), counts of specific functional groups and rotatable bonds, 
electrostatic potential data from quantum mechanical calcula tions, and a wide-range 
of topological and electronic indices such as those developed by Hall and Kier51,52. 
Standard statistical packages are usually applied for the descriptor selection in 
multiple linear regression based approaches5-7,53-55. Beside those, some novel 
methods for the descriptor selection have been described recently, e.g. Jorgensen7 
used Monte Carlo Simulation to select descriptors for the solute and water interaction, 
Wegner56 and Sahura39 used entropy-based descriptor selection. 
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4.1.1.2.2 Neural networks 
In comparison to multiple linear regression, the principal advantage of neural 
networks (NN) is related to the introduction of non-linear terms into the solubility 
equations. Furthermore, neural networks can consider descriptors in specific range of 
the measurement space. The disadvantage is that the internal processing of data in 
the NN approach is hidden. Usually, NN systems are treated as black boxes and 
often difficult to provide further insights in the nature of the major properties or 
features governing solubility. Therefore, the application of neural networks can be 
considered as promising in the treatment of large data sets with high content of non-
linearity. 
4.1.1.3 Available solubility prediction tools 
4.1.1.3.1 Available tools based on multiple linear regression 
Numerous approaches based on multiple linear regression have been  published for 
the prediction of aqueous solubility. Most studies include a large collection of various, 
relatively complex descriptors42,54,57-60. The probably most successful studies based 
on multiple linear regression approaches are from Abraham and Le5, Meylan and 
Howard6, Jorgensen and Duffy7. 
Abraham and Le5 used experimentally determined descriptors for developing the 
logS prediction and ended up with a six-descriptor model with r2 = 0.92 and rms = 
0.56 for 594 molecules. (Eq. 10) 
 
x
HHH V
HHRS
*986.3**337.3*187.4
2*124.22*813.02*02.1510.0log
222 --+
å++-=
åå å bab
ap
 Eq. 10 
where R2 is the molar refractivity, H2p  is the dipolarity, å H2a is the hydrogen-bond 
acidity, å H2b is hydrogen-bond basicity and Vx is volume. 
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Meylan and Howard6 used experimental logPo/w  and molecular weight (Mw ) as 
descriptors along with 15 correction factors (f i) to predict solubility. An r2 = 0.84 and 
rms = 0.90 was obtained for a data set of 3000 compounds. (Eq. 11) 
 å+--=
i
iwwo fMPS 00728.0log854.0796.0log /  Eq. 11 
fi describes various sub-rules accounting for the presence of specific functional 
groups. 12 compound classes are identified: aliphatic alcohol, aliphatic acid, aliphatic 
amine, aromatic acid, phenol, alkyl pyridine, azo, nitrile, hydrocarbon, nitro, SO2, 
fluoroalkane, polycyclic aromatic hydrocarbons (PAH), multi-amino acid. Each class 
of these has a corresponding fi value. å if is the sum of all correction factors 
applicable to a given compound. Each factor applies to a compound, if the related 
substructural fragment is present, but each factor is counted only once no matter how 
many times the functional group appears in a molecule. 
Jorgensen and Duffy7 selected their descriptors via a Monte Carlo (MC) simulation 
for different solutes in water. Five terms were used in the final regression equation 
and yielded r2 = 0.88, q2 = 0.87, and rms = 0.72 for 230 compounds. 
 
logS = 0.32 ESXL + 0.65 HBAC + 2.19 #amine – 1.76 
#nitro – 162 (HBAC * HBDN)1/2 / SASA + 1.18 
Eq. 12 
where ESXL is solute-water Lennard-Jones interaction energy. It is highly correlated 
with molecular size, which can be represented alternatively by SASA or volume. 
HBAC is the number of hydrogen acceptors, HBDN is the number of hydrogen 
donors, #amine is the number of non-conjugated amine groups and #nitro is the total 
number of nitro groups. 
In 2002, Jorgensen and Duffy61 developed three diverse QSPR equations for alkane, 
PAHs and remaining molecules. 
For alkanes logS = 1.302 – 0.0104 VOL Eq. 13 
For PAH class logS = 4.182 – 0.0155 VOL + 0.670 #rotor Eq. 14 
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For remaining 
molecules 
logS = 3.886 – 0.0194 SASA + 0.514 HBAC 
+ 0.578 HBDN + 1.343 #amine + 1.224 
#amide – 116 (HBAC * HBDN)1/2 / SASA + 
0.182 #rotor – 0.00405 WPSA 
Eq. 15 
where #rotor is the number of rotable bonds. #amide is the number of amides. The 
WPSA (weakly polar components of SASA) term is the surface area for all halogens, 
sulfur, and phosphorous atoms. 
Yalkowsky and Valvani53 used melting points to consider the impact of crystal state 
on solubility. A regression was achieved for 155 compounds with r2 = 0.979 and SD = 
0.308. (Eq. 16) 
 logSw  = -1.05 logPoct – 0.012(mp – 25) + 0.87 Eq. 16 
where logP is octanol-water partition coefficient. It approximates the activity 
coefficient of the un-ionized solute in water in equilibrium with the un-ionized 
molecular species in octanol. Mp is melting point in °C, an approximation for the 
relative energy it takes to break the crystal lattice of the solute. 
According to Eq. 16, the melting point is a valuable descriptor for describing the 
influence of solid state on solubility. However, the disadvantage of Yalkowsky’s 
method relates to the fact that there are currently no reliable models to predict 
melting points. Usually, experimental values have to be used, which are not suitable 
in the early drug discovery phase, because ranking schemes are necessary before 
synthesis. 
Beside the works of Meylan and Howard6, Jorgensen and Duffy61, several structural 
series orientated studies were preformed. In order to prove the molecular similarities, 
Chen54 divided a data set of 321 structurally dive rse drugs or related compounds into 
three groups, according to the Euclidean distance calculated using 8 molecular 
descriptors of the compounds. His QSAR model could predict the properties of 
unknown compounds that were structurally similar to those used to build the model. 
Delgado62 made a solubility study for chlorinated hydrocarbons, McElroy55 focused 
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on heteroatom-containing organic compounds, Nikolic63 on aliphatic alcohols and 
Yin64 on sulfur-containing aromatic esters. 
4.1.1.3.2 Available tools based on neural networks 
Tetko and Tanchuk9,65 used multiple linear regression for identifying subsets of 
significant descriptors in the application of NN. They started with three different types 
of 55 topological indices introduced by Kier and Hall51,52. These indices were 
analyzed via multiple linear regression. The resulting final equation contained 33 
significant parameters. The selected parameters were 24 E-state and six other 
topological indices including indicator variables for aliphatic hydrocarbons and 
aromaticity. Artificial Neural Networks were then applied to analyze the set of 33 
selected descriptors and a model was provided with r2 = 0.91 and RMS = 0.62 to 
estimate the aqueous solubility for a diverse set of 1291 organic compounds with 33-
4-1 neurons. 
4.1.1.3.3 Other available tools 
Klamt10 combined the COSMO-RS method, based on quantum chemical calculations, 
with a QSPR approach in order to predict the aqueous solubility of a wide range of 
typical neutral drugs and pesticides. The COSMO-RS, originally developed for the 
prediction of liquid-liquid and liquid-vapor equilibrium constants, was extended to 
solid compounds by the addition of an expression for the Gibbs free energy of fusion 
D XfusG , which was related to the free energetic difference between the compound in 
its solid and liquid state. Klamt10 first identified a small set of descriptors of potential 
significance for D XfusG . The selected descriptors were the molecular size, rigidity, 
polarity, and number of hydrogen bonds. He tried to describe D XfusG  via a QSPR 
approach. It finally turned out that the descriptor combination of cavity volume VX, the 
number of ring atoms XringatomN , and the chemical potential of a compound X in water 
( XWm ) was the best suited for the description of D
X
fusG . On a data set of 150 neutral 
drug-like compounds, the COSMO-RS model achieved a rms deviation of 0.66 log-
units. One possible advantage of this prediction method is that COSMO-RS is able to 
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predict solubility in almost arbitrary solvents and solvent mixtures due to the 
capability of COSMO-RS to estimate the chemical potential of a compound in 
arbitrary liquids.  
4.1.1.4 Performance of commercially available tools on drug-like 
compounds 
In a recent evaluation66, commercially available solubility prediction tools were tested 
on a set of 384 neutral drug-like compounds. 
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Figure 18:  Experimental minus predicted Log1/S0 versus frequency of 384 neutral compounds in each 
residual range. S0 is the molarity of the unionized molecular species. (graph from Le
66) 
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According to the results shown in Figure 18, AlogPS was the best available “off-the-
shelf package” and predicted 49.2% of the compounds within an error of 0.5 log units 
of the experimental intrinsic solubility. No single residual was above 3.5 log units for 
the 384 compounds in the data set. 
The program SRC WsKow6 was the second best solubility prediction tool after 
AlogPS. (Figure 18) Because AlogPS was not available, SRC WsKow6 was re-
evaluated with 253 more precisely characterized compounds taken from the data set 
selected by Le66. (Figure 19)  
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Figure 19:  The solubility of 253 neutral drugs predicted with WsKow6. a) Experimental minus predicted 
Log1/S0 versus frequency of compounds in each residual range; b) experimental versus 
predicted Log1/S0 . S0 is the molarity of the unionized molecular species. 
Although most residues of the 253 neutral drugs lay within 2 log units (Figure 19a), 
there was no correlation between experimental and predicted solubility. (Figure 19b) 
This finding could be confirmed by a larger data set of 2473 drug-like compounds, 
which was used for the development of an improved solubility prediction tool as 
described in the chapter 4.2.1.1.3. (Figure 20) 
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Figure 20:  Solubility prediction for 2473 drugs-like compounds using WsKow6. S0 is the molarity of the 
unionized molecular species. 
4.1.1.5 Fundamental differences between aqueous solubilities of 
compounds from the AQUASOL database and drug-like compounds 
In order to understand the reason for the poor performance in the solubility prediction 
of drug-like compounds by commercial tools, solubility values of 1770 organic 
compounds were extracted from the AQUASOL database67. Calculated properties of 
these 1770 organic compounds from AQUASOL database67 and 2473 drug-like 
compounds were examined. 
Evaluated descriptors were calculated with programs Msrfvl68 and CallistoGen69. 
Principal component analysis70 (PCA) was applied to reveal groupings in the 
observations. PCA summarized the information contained in the original variables by 
calculation of four new latent variables. The first three components described 75.9% 
of the X-space. 
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Figure 21:  PCA analysis for 1770 organic compounds from the AQUASOL database67 (blue) and 2473 
internal drug-like molecules (red). a) PCA score plot70; b) PCA loading plot70. 
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A clear separation between 1770 organic compounds and 2473 drugs was observed 
as depicted in Figure 21a. The descriptors responsible for this separation were 
molecular weight, %aromatic atoms and solubility (Figure 21b). Histograms were 
used in Table 9 to compare the important properties of 1770 organic and 2473 drug-
like compounds directly. 
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Table 9:  Comparison of molecular properties of 1770 organic and 2473 drug-like compounds. S0 is 
the molarity of the unionized molecular species. 
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Table 9 shows that in comparison to the organic compounds from the AQUASOL 
database67, drug-like compounds have higher molecular weight, and usually include 
a larger fraction of aromatic atoms and occupy poor solubility. Additionally, 1770 
compounds in the AQUASOL database67 were inspected, according to their drug-
likeness. 206 compounds were found as drug-like, resp. 11.6%. Therefore, the 
compounds in AQUASOL database67 do not represent the properties of drug-like 
molecules. Due to this drawback, the commercial tools based on data extracted from 
the AQUASOL database67 can not predict the solubility of drug-like compounds well. 
The relationship between solubility, lipophilicity and molecular weight for 1770 
organic compounds in AQUASOL database67 and 2473 drug-like compounds are 
shown in Figure 22. 
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Figure 22:  Solubility prediction using lipophilicity and molecular weight as descriptors. a) For 1770 
organic compounds in the AQUASOL67 database; b) For 2473 drug-like compounds. 
Figure 22a shows that the solubility of 1770 organic compounds in the AQUASOL 
database67 can be predicted using lipophilicity and molecular weight as descriptors. 
However, the same does not work in the solubility prediction of drug-like molecules. 
Solubility prediction of drug-like molecules seems to be more complicated in 
comparison to simple organic molecules. Thus, commercially available tools can not 
be expected to work well for the solubility prediction of drug-like compounds, 
because they are calibrated with data of simple organic compounds. 
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4.1.2 Objectives 
Solvation process and solid state related factors are governing solubility. In a large 
number of publications5,7,53,61, lipophilicity is found to describe the liquid-liquid 
interaction important for the solvation process. Melting point, hydrogen bond donor 
and acceptor counts are usually used for the interpretation of the cohesive energy in 
the crystal packing. However, the relationship between crystal packing, melting point 
and intermolecular hydrogen bonding has not been completely understood. 
Furthermore, few publications can be found dealing with the extent of the influence of 
solid state on solubility. Therefore, the first goal of the prediction part was to collect 
compounds with measured 3D structures and melting points in order to explain the 
differences in solubility caused by diverse crystal packings. The second goal was 
related to polymorphism for evaluating the impact of solid state on solubility. 
Several tools6,54,55,61-64,71-73 are available for the solubility prediction of compounds 
with certain structural or property similarities. However, most of them fail to predict 
the aqueous solubility of drug-like compounds in congeneric series, because the 
descriptors used in such tools are calibrated with small subsets of organic 
compounds. Therefore, the third goal of this part focused on the identification of 
suitable descriptors for predicting solubility of an extended large data set comprising 
of congeneric series of drug-like compounds. 
4.2 Materials and methods 
4.2.1 Materials 
4.2.1.1 Data sets 
Three data sets were collected. The first data set contained 74 compounds with 
known 3D crystal structures. The second data set contained 51 compounds with 
melting points, which were well characterized during the late development phase. 
The third data set contained 2473 compounds in 81 congeneric series. Among these 
2473 compounds, 983 were uncharged, 166 had measured pKa values and for 1324 
compounds, their pKa values were assigned according to structural similarity 
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comparisons. Additionally, the 2473 compounds were classified using the clustering 
package of Daylight74 and singletons were eliminated. 
4.2.1.1.1 Compounds with known crystal information: First data set 
74 drug-like compounds were found to have their 3D crystal structures registered in 
the internal and external Cambridge Structure Database (CSD)75. Among them, 34 
compounds had similar structures and belonged to four different series, resp. 
deoxyuridine-, diazepam-, sulfonamide- and sulfanilyurea-derivates. A large number 
of these 74 compounds showed polymorphism or pseudo polymorphism. Although 
polymorphic forms usually do not differ in their solubility to a large extent27, solubility 
prediction can be complicated due to different conformations of diverse polymorphic 
forms, when the value of solubility is dependent on 3D structures. 
Following rules for the selection of crystal structures were applied. If compounds 
occurred in both polymorphic and pseudo polymorphic forms, the polymorphic form 
was preferably taken. Usually polymorphs are energetically more stable, in 
comparison to the pseudo polymorphs. In case compounds occurred in several 
polymorphic or pseudo polymorphic forms, the conformations were compared with 
each other, using the superposition function of MOLOC68. In those cases, different 
possibilities were observed and had to be considered as described in the following: 
Case 1. Different polymorphic forms with similar conformations but different 
packing schemes. These were diazepam, progesterone, sulfamethoxazole, 
hydrocortisone, trifluorothymine, deoxyriboside, sulfameter. 
Case 2. Different polymorphic forms with different conformations and different 
packing schemes. These were bosentan, restosterone, carbamazepine, 
furosemide, diclofenac, sulfamerazine, 5-fluoro-2-deoxyuridine . 
Case 3. An asymmetric crystal unit contains two molecules with identical 
constitution but different conformations. These were testosterone, 
furosemide, sulfamethoxypyridazine, sulfamerazine, 5-fluoro-2-deoxyuridine, 
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sulfameter, medazepam, 2-methyl-4-methoxy-6-sulfanilamidopyrimidine, 3-
azido-3-deoxythymidine, prazepam, sulfabenzamide. 
According to the obtained analytical results for the different conformations, 59 
compounds with one conformation were used for the model development and 15 
compounds with more than one conformation to test the model. 
4.2.1.1.2 Compounds with known melting points: Second data set 
51 compounds with predefined solubility and melting points during the late 
development phase were found. Out of this data set, 11 compounds had measured 
equilibrium solubility values. In order to evaluate the quality of the solubility data 
determined during the late development phase, the equilibrium solubility of these 11 
compounds were listed together with the predetermined solubility in Table 10. 
Aqueous Solubility Prediction of Drug-like Compounds 
- 70 - 
Predetermined solubility Equilibrium solubility 
ID ApKa1 BpKa1 
S 
(µg/mL) 
log1/S0 Buffer 
T 
(°C) 
S 
(µg/mL) 
log1/S0 Buffer pH 
compound 2 5.7 8 7700 1.69 
Buffer 
pH=7.5 
37 6330 1.75 
Phosphate 
0.05M pH 6.5 
6.8 
compound 3 0 0 <10 <4.70 
0.1N 
HCl 
25 22 4.35 
Phosphate 
0.05M pH 6.5 
6.5 
compound 4 0 8.9 >2500 >3.32 
Buffer 
pH=7.5 
37 7740 3.71 
Phosphate 
0.05M pH 6.5 
6.6 
compound 5 0 6.13 320 3.38 
Buffer 
pH=6.8 
37 602 3.15 
Phosphate 
0.05M  pH 
6.5 
6.6 
bosentan 5.46 0 430 5.15 
Buffer 
pH=7.5 
37 14 5.77 
Phosphate 
0.05M pH 6.5 
6.6 
compound 6 0 10.29 110 8.63 
Buffer 
pH=5 
25 17 8.33 
Phosphate 
0.05M pH 6.5 
6.3 
compound 7 0 4.07 13 7.71 
Buffer 
pH=1 
25 7 6.01 
Phosphate 
0.05M pH 6.5 
3 
compound 8 7.62 4.01 0.8 5.58 
Buffer 
pH=7 
25 1 5.89 
Phosphate 
0.05M pH 6.5 
6.6 
compound 9 0 0 <0.1 >6.8 
Buffer 
pH=7 
25 1 5.80 
Phosphate 
0.05M pH 6.5 
6.6 
compound 
10 
6.66 0 0.02 8.19 
Buffer 
pH=7.5 
25 1 6.83 
Phosphate 
0.05M pH 6.5 
7.8 
compound 
11 
8.07 0 <0.02 >7.42 
Buffer 
pH=7 
25 1 5.68 
Phosphate 
0.05M pH 6.5 
6.5 
Table 10:  Overview on solubilities of 11 selected compounds measured at certain pH value and 
temperature. 
Table 10 shows that the predetermined solubilities agree with data determined via 
the equilibrium solubility method, except for compound 10. Thus, the predetermined 
solubility data of all these 51 compounds were considered as well characterized and 
used in the further development of a new solubility model. 
4.2.1.1.3 Compounds belonging to congeneric series: Third data set 
2473 compounds with measured equilibrium or HT-solubilities were collected. Before 
the solubility data of these 2473 compounds were combined and used in the 
development of the prediction tool, the available solubility data obtained by both 
methods were compared. 
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Figure 23: Comparison of solubility data obtained using equilibrium and HT solubility measurements. 
S is the molarity of molecular species. 
Figure 23 shows the correlation of both solubility measuring methods. Usually, data 
generated by these methods do correlate well. Due to the differences in the solid 
state properties, sometimes, differences can occur in solubilities when lower 
crystallinity is obtained after lyophilisation or compounds with low molecular weight 
are lost during the evaporation process. Therefore, HT solubility results were left out, 
when compounds showed high tendency to form amorphous materials. 
4.2.1.1.4 Criteria for selection of high quality solubility data 
Solubility data were collected for neutral and ionizable compounds. In order to 
overcome difficulties due to the ionization, the intrinsic solubility was calculated 
according to the Henderson-Hasselbalch76 equation. The aqueous solubility used for 
prediction was expressed as log1/S0. S0 is the molarity of the unionized molecular 
species. 
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In order to ensure high quality data used for the development of prediction tools, all 
three data sets mentioned above were selected based on the following criteria: 
1. Availability of aqueous solubility data determined by potentiometric titrations 
with 0.15 N KCl as background solution or by equilibrium solubility and HT-
solubility methods with 50 mM phosphate as buffer. In case of equilibrium and 
HT solubility measurements, pH value of the saturated solution and 
measurement temperature were registered. 
2. The solubility of compounds available as salts were considered, when no large 
pH shift was observed for saturated solutions or the intrinsic solubility of the 
neutral form was determined via the potentiometric method. 
3. HT-solubility data were only taken, when compounds did not show high 
tendency to form amorphous materials. 
4. Ionizable compounds were used in the data set only if their pKa values were 
known or could be derived from structural similar compounds. 
5. For the first data set, crystal structures were collected from the Roche X-ray or 
Cambridge structure database (CSD)75. 
6. For the second data set, the experimental melting points were mandatory. 
4.2.1.2 Descriptors 
4.2.1.2.1 Property based descriptors 
35 descriptors assumed to influence both the crystal energy and solute water 
interactions were considered to model solubility. Except melting points which were 
experimentally determined, the other 34 descriptors were calculated. These 34 
descriptors were used to express the molecular size, polarity, flexibility, rigidity, 
electronic properties, formation of hydrogen bonds, hydrophilicity and lipophilicity of 
the molecules. 
A detailed overview on used 2D and 3D descriptors is given in Table 11, together 
with the information on the applied software packages. 
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Dimension Descriptors Tools 
molecular weight 
the number of aromatic rings 
the number of non aromatic rings 
the number of possible internal hydrogen bonds 
the number of rotable bonds 
the number of nitrogen and oxygen atoms 
the number of aromatic atoms 
the number of aliphatic carbons 
CALLISTOGEN69 
lipophilicity 
KOWWIN6 
ClogP77 
2D 
pKa ACD78 
molecular volume and surface 
hydrophilic volume and surface 
hydrophobic volume and surface 
the number of hydrogen donors and acceptors 
the maximum, minimum and mean value of the 
hydrogen donor and acceptor strength 
rotational volume 
ovality 
Rg 
d0, d1, d2 
MOLOC68 
Emin1-3 
HL1-2 
A 
CP 
Volsurf79 
3D 
dipole moment 
polarizability 
HOMO LUMO gap 
VAMP80 
Table 11:  2D and 3D descriptors listed together with the applied softwares. For explanation of d0, 
d1, d2, Emin1-3, HL1-2, A, CP see the chapter of Abbreviation. 
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Before the calculation of 3D descriptors for the first data set, the crystal structures 
obtained from CSD75 were inspected for the correct adjustment of hydrogen atoms 
using MOLOC68. 3D descriptors were then generated by keeping the crystal 3D 
structure fixed. 3D descriptors for the second data set were derived after the 
conversion of 2D to 3D-structures using CORINA81. 
In order to evaluate the quality of the calculated parameters used in the development 
of improved solubility prediction tools, measured and calculated descriptors were 
compared. 
4.2.1.2.2 Evaluation of the property based descriptors 
4.2.1.2.2.1  Dipole Moments 
Dipole moments were calculated using VAMP80. VAMP80 is a AM1 based method 
which uses the natural atomic orbital/point charge (NAO-PC) model to calculate the 
molecular electrostatic potentials. Calculated VAMP80 dipole moments were 
compared with experimentally measured ones to estimate their quality. (Table 12, 
Figure 24) 
 
 
 
 
 
 
Table 12:  9 compounds with experimental 
and calculated dipole moments. 
 
Molecule 
Dipole 
moment(vamp80) 
[Debye] 
Dipole 
moment(exp) 
[Debye] 
C2H5OH 1.57 1.69 
C6H5CH3 0.47 0.36 
CH2Cl2 1.51 1.57 
CH3Cl 1.68 1.87 
CH3OH 1.70 1.71 
CHCl3 0.99 1.01 
H2O 1.87 1.85 
NH3 1.92 1.47 
C6H4(CH3)2 0.78 0.62 
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Figure 24:  Comparison of experimental and 
calculated dipole moments using 
VAMP80. 
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In Table 12, 9 small organic compounds are listed and their predicted dipole 
moments meet experimental values well. (Figure 24) 
Dipole moment (GAUSSIAN
82
) 
[Debye] 
Dipole moment (VAMP
80
) 
[Debye] Molecule 
AM1 DFT/6-31g* HF/6-31g* AM1/NAO 
compound 12 3.09 2.63 3.07 3.74 
Diazepam 3.28 3.08 3.53 3.55 
Dimethomorph 2.18 1.99 2.04 2.33 
compound 13 1.6 1.91 2.03 2.14 
Table 13:  4 drug-like compounds are listed together with their dipole moments calculated with 
GAUSSIAN82 and VAMP80. 
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Figure 25: Graphical comparison of dipole moments calculated with VAMP80 and GAUSSIAN82. 
In the case of unknown dipole moments, dipole moments were calculated with 
Gaussian82 using AM1, DFT/6-31g* and HF/6-31g* methods and the results were 
compared with the dipole moments calculated via VAMP80. (Table 13, Figure 25) It is 
well known, that 6-31g* ab initio methods give the most similar electronic property 
results to those observed in the X-ray structure83-85. However, for the four drug-like 
molecules, it took two hours to do electropotential calculations with DFT and two 
days with HF. Therefore, the AM1 method of VAMP80 was the preferred choice for 
the calculation of dipole moments. It was much faster and the dipole moments 
calculated with VAMP AM1 were close to those obtained with ab initio methods. 
(Table 13, Figure 25) 
4.2.1.2.2.2  Lipophilicity 
Lipophilicity is an important descriptor for the prediction of solubility. 664 compounds 
with experimentally measured lipophilicity values were selected out of the third 
database to evaluate the error of the lipophilicity calculation program, e.g. ClogP77. 
These 664 compounds were classified in 51 congeneric series using the clustering 
package of Daylight74. 611 of them were uncharged and 53 had measured pKa 
values. The LogP values of charged compounds were calculated, according to the 
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Henderson-Hasselbalch76 equation, using measured LogD and pKa values as input 
parameters. 
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Figure 26:  Experimental lipophilicity of 664 compounds is plotted against ClogP77. 
In Figure 26, experimental lipophilicities are plotted against the values calculated with 
ClogP77. It is obvious that the values calculated with ClogP77 do not correspond to the 
experimental lipophilicities. The average standard error between ClogP77 and 
experimental value was ±0.849 log units. 
Nevertheless, the correlation between experimental and calculated lipophilicity could 
be improved via Eq. 17, which took the index of congeneric series as additional 
indicator variables into consideration. 
 bfcPCaLogP
n
i
iseriesi +å+=
=1
,*log*  Eq. 17 
where a is the coefficient of ClogP77. ci is the constant for the congeneric series 
fseries,i,. b describes the constant term in Eq. 17. 
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Figure 27:  The lipophilicity of 664 compounds in 51 congeneric series is calculated with Eq. 17 and 
plotted against experimental logP. Different colors and shapes are used to identify these 51 
congeneric series. 
R2 = 0.597, Q2 = 0.482 and rmse = 0.481 were calcula ted using SIMCA70. The 
correlation between experimental and calculated lipophilicity was improved. The 
average standard error between calculated and experimental lipophilicity was ±0.371 
log units. Hence, the congeneric series index can be used to correct the error in the 
lipophilicity calculation for diverse scaffolds and is helpful in the improvement of the 
solubility prediction for the compounds in the third data set. 
4.2.1.2.2.3  Melting Points 
The melting point is an useful factor for studying the solid cohesive energy of crystal 
packing. 51 compounds of the second data set were used to testify the predictive 
power of the program MPBPVP86,87, which is the only commercially available tool for 
this task. (Figure 28) 
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Figure 28:  Comparison of experimental and calculated melting points using MPBPVP86,87. 
Figure 28 shows that program MPBPVP86,87 fails to sufficiently predict the melting 
points of the second data set. Therefore, a new model had to be developed, in order 
to allow the consideration of melting points in the solubility prediction. 
4.2.1.2.2.4  pKa 
pKa values were considered in the calculation of the solubility shift caused by the 
ionization. In case when no experimental pKa values were available, the program 
ACD78 could be used to predict the ionization constants. In order to evaluate the 
predictive power of ACD78, 23 structural similar compounds were selected and are 
listed together in Table 14. The first 13 compounds in Table 14 had their pKa values 
measured and the remaining 10 compounds had no measured pKa values. 
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Nr. Structure BpKa (exp) BpKa (ACD) S (µg/mL) pH 
1 9.85 4.09 - - 
2 9.81 4.26 - - 
3 9.92 3.99 - - 
4 9.99 4.04 - - 
5 10 4.17 - - 
6 9.67 3.61 - - 
7 9.97 4.19 - - 
8 9.55 4.05 - - 
9 9.46 3.83 - - 
10 9.86 4.49 - - 
11 9.54 4.24 - - 
12 9.11 3.15 - - 
13 9.23 3.94 - - 
14 - 4.26 5 6.5 
15 - 3.92 303 6.5 
16 - 4.27 229 6.5 
17 - 4.11 36 6.5 
18 - 4.27 6 6.5 
19 - 3.67 14 6.5 
20 - 3.67 27 6.5 
21 - 4.26 390 6.5 
22 - 3.93 84 6.5 
23 
NAliphate
N
R1
R2
[n]  
- 3.97 6 6.5 
Table 14:  Comparison of experimental and calculated pKa values. The calculation was performed 
with ACD78 for 23 structural similar compounds. 
Experimental and calculated pKa values of the first 13 compounds were compared, in 
order to decide whether pKa calculated by ACD78 could be taken for the compounds 
without experimental pKa values. In comparison with otho- and meta-substituted 
quinoline derivates, the para-substituted ones are known to have a high base pKa 
value. An average BpKa could be calculated to 9.68 for the first 13 compounds in 
Table 14 using the experimentally measured data. The standard error of pKa shift 
caused by different substituent patterns was ±0.24 log units. However, ACD78 treated 
the para-substituted quinoline derivates as compounds containing isolated quinoline 
moieties. Much lower base pKa values were calculated using ACD78 than the 
experimentally determined. In order to overcome the limitations of the calculation tool 
for drug-like compounds, pKa values were adjusted considering information on 
structural similar compounds where several measured values of pKa existed. For 
example, for the last 10 compounds listed in Table 14 with known solubility but 
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unknown pKa values, the formerly calculated average pKa = 9.68 with a standard 
error of ±0.24 log units were used in the prediction tool development for the 
correction of solubility shift caused by ionization. Such manual pKa adjustment was 
performed for 2473 compounds collected in the third data set for the development of 
an superior solubility prediction tool, as well. Among them, 983 were uncharged at 
pH = 6.5, 166 had their pKa values measured and for the remaining 1324 charged 
compounds, pKa values were assigned as described. 
4.2.1.2.3 Fragment based descriptors 
The structural fragmentation scheme of ClogP77 was found to be the easiest way to 
obtain molecular fragments. In ClogP77, the molecules are dissected according to the 
rule of “Isolating Carbon”. An “Isolating Carbon” atom (IC) is a carbon which is not 
double- or triple-bonded to a hetero atom77. Isolating carbons can, however, be 
multiply bonded to one another, such as those in CH3CH=CH2. An IC is an atomic 
fragment that, for calculation purposes at least, is always hydrophobic. Any hydrogen 
atom attached to an isolating carbon (ICH) is also a hydrophobic atomic fragment. All 
atoms or groups of covalently bonded atoms that remain after removal of ICs and 
ICHs are polar fragments. Thus a polar fragment contains no ICs but each has one 
or more bonds to ICs. These bonds are used to label the environments of a polar 
fragment, and are usually designated as A for aliphatic, Z for benzyl, V for vinyl, Y for 
styryl and a for aromatic. 
Smarts77 is a language for the specification of substructures using rules that are 
straightforward extensions of Smiles77. In order to enable flexible and efficient 
fragment search, Smarts77 notations were used to reproduce the five connection 
environments defined in ClogP77. (Table 15) 
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Type Symbol Smarts 
Alkyl A [C; !$(*=,#[!#6]); !$(C(-*)a; !$(*=C)] 
Benzyl Z [C; !$(C=*); $(C(-*)a)] 
Vinyl V [C; $(*=C); !$(*=Ca); !$(*(=C)a] 
Styryl Y [C; $(*=Ca); $(*(=C)a)] 
Aromatic a [c; !$(*=, #[!#6])] 
Table 15:  Smarts77 notations for the five connection environments of the “Isolating Carbon”. 
The difference in the application of ClogP77 connection environments and the newly 
defined ones is shown for benzyl and styryl substituents on the first position of hetero 
aromatic ring system. (Table 16) 
Nr. Hydroxyl group Newly defined Fragment ClogP fragment 
1 N
OH
 
(Z)[OH] 
(A)[OH] 
not correct 
2 
N
OH  
(Z)[OH] (Z)[OH] 
3 N
OH
 
(Y)[OH] 
(V)[OH] 
not correct 
4 
N
OH  
(Y)[OH] (Y)[OH] 
Table 16:  Comparing the definition of newly defined connection environments with ClogP77. A and Z 
as defined in Table 15. 
Table 16 shows that ClogP77 treats the nitrogen atom in pyrrole rings as an aliphatic 
atom, which is not chemically right defined. In contrast, the newly-defined connection 
environments overcome this problem. The same nitrogen atom is correctly handled 
as an aromatic atom, which meets the chemical definition of aromatic atom well. 
Thus, the hydroxyl group in compound 1 and 3 is correctly recognized as benzyl and 
styryl bounded substituent using the newly-defined connection environments. 
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Additionally, the ClogP77 fragments are so defined that each heavy atom in the 
molecule belongs only to one certain fragment. Thus, the presence of fragments can 
be easily checked. Eq. 18 shows, the total number of heavy atoms in a molecule 
should be equal to the sum of the number of the heavy atoms in the fragments. The 
precondition for this equation is the availability of all fragments of this molecule in the 
newly developed database. 
 Nr heavy atoms of a molecule = å
=
n
i 1
Nr heavy atoms of a fragment  Eq. 18 
where n is the number of the fragments in a molecule. 
Due to this simplified test method for missing fragments, ClogP77 fragments were 
preferably used to Kowwin LogP6 fragments as descriptors for the development of 
solubility prediction tool.  
In addition to the 170 structural fragments defined in the chapter Appendix, four 
fragments were used as correction factors to improve the predictive power of the new 
solubility tool. (Table 17) 
Fragments as correction factors Structures 
Aliphatic ring    
Trifluoromethyl C(F)(F)F F
F
F
 
aS(=O)(=O)[NH]c1sc2ccccc2n1  N
S
N
H
S
O
O
 
s1ccc2ccccc12 S
 
Table 17:  Four correction factors for the solubility prediction. 
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4.2.1.2.3.1  Evaluation of the fragment based descriptors 
Fragment based descriptors were used to predict the solubility of drug-like 
compounds in congeneric series. Figure 29 takes the derivates of diazepam as 
example to demonstrate the usage of fragments. Usually, increasing the lipophilicity 
and the molecular weight results in reduced solubility6. However, diazepam and 
temazepam have higher solubility values than nordiazepam and oxazepam, although 
their lipophilicity and molecular weight is higher. (Figure 29) 
 
 
  
Nr Compound Structure MW Melting point (°C) ClogP Log1/S0 
1 Bromazepam N
N
N
H
Br
O
 
316.16  1.703 3.09 
2 Prazepam 
N
N
Cl
O
 
324.81  4.143 4.67 
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3 Nordiazepam N
N
H
Cl
O
 
270.72 216 3.021 4.23 
4 
7-Chloro-5-(o-chlorophenyl)-1,3-
dihydro-2H-1,4-benzodiazepin-2-
one 
N
N
H
Cl
O
Cl
 
305.16  3.084 3.97 
5 Temazepam N
N
Cl
O
OH
 
300.74 119 2.549 3.51 
6 Diazepam N
N
Cl
O
 
284.75 132 3.17 3.83 
7 Medazepam N
N
Cl
 
270.78  3.71 4.41 
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8 Oxazepam N
N
H
Cl
O
OH
 
286.72 197 2.305 4.12 
Figure 29:  The correlation between solubility, lipophilicity and molecular weight for diazepam derivates. 
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e) 
 
f) 
Figure 30:  a) 2D structure of nordiazepam; b) 2D structure of diazepam; c) 3D crystal structure of 
nordiazepam; d) 3D crystal structure of diazepam; e) crystal packing of nordiazepam; f) 
crystal packing of diazepam. 
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Figure 31:  a) 2D structure of oxazepam; b) 2D structure of temazepam; c) 3D crystal structure of 
oxazepam; d) 3D crystal structure of temazepam; e) crystal packing of oxazepam; f) crystal 
packing of temazepam. 
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The abnormal solubility phenomenon observed for the benzodiazepines (Figure 29) 
can be explained by comparing the compounds’ crystal structures and melting points. 
The N-alkylation of the amide group in the temazepam replaces the amido hydrogen 
atom in oxazepam, which is responsible for strong hydrogen and dipolar bonding 
within the crystal lattice. The melting point of temazepam is lower than that of 
oxazepam, which illustrates the remarkable impact of eliminating the amido hydrogen 
atom of the oxazepam molecule. The crystal structures shown in Figure 30 and 
Figure 31 reflect the effect of amido hydrogen atom, as well. The flat layer of 
oxazepam in the crystalline state is the result of its strong hydrogen bonding, which 
makes the process of dissolution much more difficult than for temazepam. An 
analogous example has been described by Goosen88 on a series of thalidomide and 
its N-alkyl analogues. Therefore, two fragments, resp. (*)N(*)C(*)=O and 
(*)[NH]C(*)=O can be used as descriptors to consider the influence of the crystal 
lattice on the solubility and distinguish the methyl group as present in temazepam 
from the general aliphatic chains. Due to hydrogen bonding, diazepam and 
temazepam have higher solubilities than nordiazepam and oxazepam, despite of its 
higher molecular weight. Thus, in the series of diazepam derivates, the negative 
proportionality of molecular weight to log1/S0 shows, that the molecular weight is not 
always a suitable descriptor for solubility prediction. The prediction of solubility can 
be improved when structural based fragments are used as descriptors, instead of 
molecular weight. 
Inspecting the calculated lipophilicity of the benzodiazepines, several anomalies were 
detected. The increment of lipophilicity caused by methyl group is usually about 0.5 
log unit. However, the ClogP77 values of diazepam and nordiazepam differ only by 
0.15 log units, although diazepam occupies a methyl group more than nordiazepam. 
Therefore, experimental values were collected  in order to analyze the effect of small 
structural differences on lipophilicity. 
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 DLogP1-2 = 0.5  
N O
 
LogP = -0.07 
1 
N O
 
LogP = -0.54 
2 DLogP1-3 = 
0.03 
N
H
O
 
LogP = -0.1 
3 
N
H
O
 
LogP = -0.85 
4 
DLogP2-4 = 
0.3 
 DlogP3-4 = 0.75  
Table 18:  The experimental lipophilicity89 of four similar cyclic amides. 
N O N O
N OO N OO
LogP = -0.85 LogP = -0.54 LogP = -0.04
LogP = -0.04LogP = -0.95LogP = 0.26
N
H
O
N
H
OO
 
Figure 32:  The experimental lipophilicity89 of six similar cyclic amides. 
Table 18 and Figure 32 show that the change in lipophilicity by the addition of an 
amido methyl group is normally DLogP = 0.3, much smaller than a normal methyl 
group (DLogP = 0.5).  
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According to these findings, a fragmental constant for the amido methyl group was 
introduced and used in the model development for the third data set. 
4.2.2 Methods 
4.2.2.1 Data analysis 
Multivariate data analysis was performed using the program SIMCA70. Variable 
preprocessing was performed. Thus, all the descriptors were mean-centered and 
scaled to unit variance (UV). Descriptors with a higher skewness than 1.5 were log-
transformed. Principal component analysis (PCA) was performed to get an overview 
on the data sets. The information contained in original variables was summarized by 
calculation of new latent variables. The compounds, which could not be well 
explained with the latent variables were classified as outliers in PCA. Outliers 
conforming to the overall correlation structure, but occupying extreme characteristics 
were strong outliers and were identified using the 95% tolerance interval signified as 
ellipse in the PCA loading plot70. Outliers found by inspecting residuals for each 
observation were moderate outliers and were identified by the “distance to the model 
in X space” (DModX) plot70. Furthermore, PCA loading plots were used to detect 
reason for the outliers in PCA and were sometimes helpful in explanation of PLS 
results. Projections to latent structure (PLS) was performed to predict solubility. The 
goodness of fit of a PLS model was given by a regression coefficient R2. The 
goodness of prediction was evaluated by a cross-validated R2, designated as Q2. The 
Q2 value was the main criterion for assessing the quality of a model. In general, a 
model with a Q2 of 0.3 or higher is statistically meaningful, while a Q2 greater than 0.5 
is regarded as a good model and 0.9 or above is excellent70. Variable Influence on 
Projection (VIP) estimated the influence of every original variable on the matrix Y. 
Variables with larger VIPs were the most relevant for explaining Y, and those with 
VIPs less than 0.8 were of lesser importance70.  
The PLS models were refined through stepwise selection of the variables and 
exclusion of the outliers. The excluded variables were those which showed 
colinearity with other variables or had low importance on solubility prediction. A 
variable was excluded, if a more predictive model (higher Q2) was obtained after 
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exclusion. There were two criteria for identifying real outliers. First, the experimental 
value was wrong. Second, the compound showed great standard deviation in PLS Y-
residue and its extreme characteristics caused heterogeneity in X-matrix. If by 
removing an outlier, the model was greatly improved, that outlier was dropped from 
the data set permanently. This refinement procedure was repeated until no further 
improvement of the model was achieved. 
Once a model was chosen, it was validated by a permutation test using scrambled Y 
values to ensure that the model was not obtained by chance. The result of the 
response permutation test was summarized in the validation plot in SIMCA70. The R2- 
and Q2 intercept in the validate plot are interpretable as measures of the significance 
of the model’s predictive power70. A model with R2Y-intercept below 0.3 -0.4 and the 
Q2 intercept below 0.05 can be assumed not to be overfitted70. 
In case of large data sets (N >100), the data set was divided into a training data set 
and a test data set. A PLS model usually was built by only using the training data set 
and obtained model was tested with an independent test data set. When additional 
observations were available, they were also used to test the predictive power of the 
model. 
4.3 Results and discussions 
4.3.1 Melting point prediction 
51 compounds of the second data set were used to develop an improved model for 
the prediction of melting points. 
After the PCA analysis and descriptor selection, three outliers were detected and left 
out of the model. The first one had a melting point of 44°C, while the other 
compounds had melting points in the range of 80 to 300°C (Figure 33a) and therefore 
were excluded. The second one was identified to have a higher melting polymorphic 
form and therefore its current registered melting point was not reliable. The third one 
showed the highest residue value in the resulting PLS model and exclusion of this 
compound enhanced the predictive power of the model dramatically. After outlier 
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detection, a much more improved model (Eq. 19), in comparison to the program 
Mpbpvp86,87, was obtained with R2 = 0.625, Q2 = 0.518 and rmse = 36.601 for 48 
compounds. (Figure 33) 
 
MP (°C) = 13.3671 * the number of hydrogen donors – 
12.7269 * LumoHomo gap + 12.19 *the maximum value of 
hydrogen donor strength + 70.4612 * the maximum value of 
hydrogen acceptor strength + 15.0007 * the number of 
aromatic rings – 85.8744 * rotational volume + 213.05 
Eq. 19 
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Figure 33:  The final melting point model. a) Correlation between experimental and predicted melting 
point; b) PLS VIP plot; c) PLS coefficient plot; d) PLS permutation test. 
Descriptors used in Eq. 19 are listed in the VIP plot (Figure 33b), according to their 
importance for explanation of melting points. The number of hydrogen donors (don) 
was found as the most important descriptor followed by LUMO HOMO Gap, the 
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maximum value of hydrogen donor strength (HD max), the number of aromatic rings, 
the rotable volume and the maximum of hydrogen acceptor strength (HA max). The 
coefficient plot (Figure 33c) shows that the most descriptors responsible for hydrogen 
bonding were positively correlated to melting point (don, HD max, HA max) except 
LUMO HOMO Gap, which could be used to describe the hydrogen bonding strength. 
The higher the gap between LUMO and HOMO, the more energy is necessary to 
bring the electron from HOMO to LUMO orbital and more difficult is the formation of 
hydrogen bonds. Therefore, the LUMO HOMO Gap in Figure 33c showed a negative 
proportionality to the melting point. Furthermore, ring structures were found to 
increase the melting point, whereas a large degree of molecular flexibility resulted in 
a lowered melting point. The permutation test shows that the PLS model was well 
validated. 
The important variables detected in the above mentioned model express similar 
molecular properties as those used by Bergström90 in her melting point study of drug-
like compounds. In order to reproduce the prediction results obtained by Bergström90, 
her training data set with well characterized melting points was taken and used for 
the model development.  
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Figure 34:  Melting point model developed using the training data set of Bergström90. a) Correlation 
between experimental and predicted melting points; b) PLS VIP plot; c) PLS coefficient plot 
d) PLS loading plot. 
A melting point model was obtained with R2 = 0.51, Q2 = 0.463 and rmse = 38.6761. 
The VIP plot shows the most important descriptors detected in this melting point 
model were responsible for the molecular flexibility, rigidity, polar surface and the 
formation of intermolecular hydrogen bonds, which agreed with the descriptors 
identified by the former melting point model and the original published model of 
Bergström90. The coefficient plot shows that melting points increased with the 
formation of hydrogen bonds, polar surface, the molecular rigidity and decreased with 
the molecular flexibility. The loading plot shows the contribution of the descriptors to 
the melting point was similar weighted as those in the model of Bergström90. 
The obtained model was validated using the test data set of Bergström90 and 48 
compounds of the second data set. (Figure 35) 
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Figure 35:  Melting point model validated with a) the test data set of Bergström90; b) 48 compounds of 
the second data set. 
Figure 35 shows that the developed model could be used to predict the melting 
points of the test data set of Bergström90 and the 48 compounds of the second data 
set. 
According to the frequency plot showed for the Bergström90 data set together with 48 
compounds of the second data set, melting points can be divided into three 
categories. 
Histogram
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50 70 90 110 130 150 170 190 210 230 250 270 290
10
20
30
40
50
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Melting Point (°C)  
Figure 36:   Frequency plot of the Bergström90 data set (red) and 48 compounds of the second data 
set (blue). The bars present the bin centers ± 10 °C. The dashed lines show the cutoff 
between low, intermediate and high melting point values. 
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Figure 36 shows the majority of compounds displayed melting points between 120 
and 180°C. Thus, 120 and 180 °C were used as thresholds to define low, 
intermediate and high melting point values. The classification results are listed in 
Table 19 and more than 50% of drug-like compounds with melting points from 
medium to high were correctly classified. 
Melting point (°C) % correctness 
40 - 120 43.6 
120 - 180 61.2 
180 - 300 64.3 
Table 19:  The correctness of melting point classification. 
4.3.2 Solubility prediction considering crystal structure 
information 
74 compounds of the first data set were divided into two data sets, according to the 
diversity in the conformations of the polymorphic forms. As already described in 
chapter 4.2.1.1.1 , 59 compounds of the first data set had only one conformation in 
the internal and external CSD75 database. Calculated 3D descriptors for the 
remaining 15 polymorphic compounds with more than one conformation were quite 
similar. Therefore, for the first data set, 3D descriptors were considered independent 
on the conformation. Hence, all 74 compounds were used for the development of a 
solubility prediction model. Lipophilicities of some compounds were found to be 
falsely calculated. Their experimental and calculated lipophilicities are listed together 
in the following tables. (Table 20 and Table 21) 
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Name Structure KowlogP ClogP logP (exp) 
sulfisomidine 
S
NH
OO
NN
2
H
N
 
0.757 1.097 -0.3 
sulfamethazine S
N
H
OO
N
N
N2H  
0.757 1.097 0.89 
sulfisoxaz ole 
S
N
H
OOO
N
2
H
N
 
1.031 0.222 1.15 
sulfadimethoxine NH
N
S O
O
N OO
N
2
H
 
1.174 1.981 1.56 
sulfamethoxazole S
N
O
O
N
NH2
O
 
0.484 0.563 1.75 
sulfadoxine NH
N
O
S
N O
O
O
N
2
H
 
-0.238 1.231 1.06 
sulfadiazine S NH
O
O
N
N
N2H
 
-0.338 0.1 -0.13 
sulfamethoxypyridazine S
N
H
O O
N
N2H
N
O
 
0.198 0.41 0.4 
sulfamerazine S
N
H
OO N
N
N2H  
0.21 0.599 0.13 
sulfameter S
NH
O
O
N
N
N2H
O
 
-0.257 0.648 0.46 
2-methyl-4-methoxy-6-
sulfanilamidopyrimidine NH
N
S
O
O
N O
N2H
 
0.745 1.547 0.61 
Table 20:  Comparison of the experimental and calculated lipophilicities for sulfonamide derivates. 
Table 20 shows the lipophilicity of sulfonamide derivates were not correctly 
calculated, therefore the experimental values collected from MedChem89 database 
were used instead of the calculated ones. The same was true for L-phenylalanine 
and an additional internal compound of the data set. 
Aqueous Solubility Prediction of Drug-like Compounds 
- 98 - 
Name Structure KowlogP ClogP logP (exp) 
L-phenylalanine 
NH3+
O
O
 
-1.283 -1.556 1.114 
compound 14  4.212 4.38 5.3 
Table 21:  Comparison of the experimental and calculated lipophilicity for L-phenylalanine and an 
internal compound. 
After the PCA analysis, descriptor selection and outlier detection, a PLS model was 
generated for 70 compounds with R2 = 0.827, Q2 = 0.79 and rmse = 0.576 (Eq. 20), 
where four outliers were omitted. 
 
Log1/S0  = 0.628723 * KowlogP + 0.0088498 * MW + 
0.239609 * the number of hydrogen donors - 0.814466 * the 
number of possible intramolecular hydrogen bonds – 
0.649414 
Eq. 20 
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Figure 37:  The final solubility model. a) Correlation between experimental and predicted solubility 
values; b) VIP plot; c) coefficient plot. 
Descriptors used in Eq. 20 are shown in the VIP plot (Figure 37b), according to their 
importance for explanation of solubility in this model. Lipophilicity was found to be the 
most important descriptor followed by molecular weight, the number of hydrogen 
donors and the number of possible intramolecular hydrogen bonds. The coefficient 
plot shows (Figure 37c) that possible formation of intramolecular hydrogen bonds 
increased the value of solubility. Additionally, the higher the lipophilicity, molecular 
weight and the number of hydrogen donors, the lower the solubility. Furthermore, the 
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importance of hydrogen donors, used in Eq. 20 confirmed the relationship between 
solubility and cohesive energy in solid state. 
O
O
NH
O
O
O
O
 
a) 
O
O
NH3+
 
b) 
Figure 38:  Two Outliers. a) Colchicine; b) L-leucine. 
Four outliers were detected and not included in the model generation. The first and 
second one had a molecular weight higher than 600 Da, while the others had a 
molecular weight in the range between 100 and 450 Da. The third one was colchicine, 
whose relative high solubility value (log1/S0 = 1.24) could not be correctly predicted 
using its molecular weight (MW = 399.4 Da) as descriptor in this model. Exclusion of 
colchicine improved the predictive power of the model dramatically. The fourth one 
was L-leucine, the only compound in this data set without aromatic ring in its 
structure. 
In Figure 37a, propranolol and sulfadiazine show the largest deviation between 
experimental and predicted solubility values. The prediction error of propranolol could 
be a result of its falsely calculated values of descriptors. According to the crystal 
structure registered in the CSD75 database, no intramolecular hydrogen bond was 
observed for propranolol, although two intramolecular hydrogen bonds were 
calculated which led to a reduced predicted solubility value. 
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Sulfadiazine Sulfamethazine 
N
NN
S
O
O
H
N
H
H
 
a) 
N
NN
S
O
O
N
H
H
H
 
b) 
 
c) 
 
d) 
 
e) 
 
f) 
Figure 39:  a) 2D structure of sulfadiazine; b) 2D structure of sulfamethazine; c) 3D crystal structure of 
sulfadiazine; d) 3D crystal structure of sulfamethazine; e) crystal packing of sulfadiazine; f) 
crystal packing of sulfamethazine. 
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Figure 39 shows that sulfadiazine and sulfamethazine have similar 2D structures, 
differing only by two methyl groups. However, by losing two methyl substituents, the 
molecular moiety containing the pyrimidine ring is in case of sulfadiazine flatter than 
sulfamethazine. Therefore, in contrast to sulfamethazine, the pyrimidine rings of 
sulfadiazine can be superimposed directly on top of each other and molecules build 6 
intermolecular hydrogen bonds, which would lead to a higher density in the crystal 
packing, a higher energetic cost for crystal lattice degradation and therefore a poorer 
solubility. 
Name KowlogP logP (exp) ApKa S (µg/mL) pH log1/S0 (exp) log1/S0 (pred) MP (°C) 
Sulfadiazine -0.338 -0.13 7.45 113 6.5 3.8 2 255-256 
Sulfamethazine 0.484 1.75 6.5 525 6.5 2.87 2.91 178-179 
Table 22:  The calculated and experimental lipophilicity, melting points and solubility of sulfadiazine 
and sulfamethazine. 
Table 22 indicates that a higher melting point as a result of more intense crystal 
packing of sulfadiazine leads to lower solubility, although the lipophilicity of 
sulfadiazine is lower than sulfamethazine, which would indicate a trend in the other 
direction. Therefore, the significant prediction error for sulfadiazine can be assumed 
as a result of insufficient consideration of solid state properties. 
4.3.3 Solubility prediction using melting point as a 
parameter 
51 compounds of the second data set were used to develop a solubility prediction 
model, by considering melting point information. After PCA analysis, descriptor 
selection and outlier detection, a PLS model (Eq. 21) with R2 = 0.811, Q2 = 0.746 and 
rmse = 0.677 was obtained for 44 compounds, while seven outliers were identified 
and omitted. 
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d) 
Figure 40:  The final solubility model. a) Correlation between experimental and predicted solubility; b) 
PLS VIP plot; c) PLS coefficient plot; d) PLS permutation test. 
 
Log1/S0  = 0.344659 * KowlogP + 0.0076349 * MW + 
0.169565 * the number of hydrogen donors + 0.00251848 * 
MP – 0.216864 * HL1 + 0.159355 
Eq. 21 
Descriptors used in Eq. 21 are listed in Figure 40b. According to its importance for 
explanation of solubility, lipophilicity was found as the most important descriptor 
followed by molecular weight, the hydrophilic-lipophilic balance, the number of 
hydrogen donors and melting point. The coefficient plot shows (Figure 40c), the 
higher the lipophilicity, molecular weight, the number of hydrogen donors, melting 
point, the lower the solubility. Additionally solubility increased with higher values of 
hydrophilic-lipophilic balance in molecule. The permutation test (Figure 40d) shows 
that the obtained PLS model was not overfitted. 
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Seven outliers were detected and left out, mainly due to exceptionally low or high 
descriptor values lying out of the covered descriptor range or possibly imprecise 
solubility values. 
4.3.4 Solubility prediction for drugs in congeneric series 
The third data set containing 2473 compounds in 81 congeneric series was used to 
develop an improved model for solubility prediction. Lipophilicity, 170 structural 
fragments plus 4 fragmental based correction factors and 81 congeneric series 
indices were used in the model generation. A model (Eq. 22) with R2 = 0.844, Q2 = 
0.79 and rmse = 0.510 was obtained for 1515 compounds in the training data set. 
The quality of the model was tested with 958 compounds in the test data set and R2 
= 0.813 was obtained. 
 7551.3**log*131493.0/1
81
1
,
174
1
0 +å+å+=
=
=
=
=
n
i
iseriesi
n
i
ii fcfragbPCSLog  Eq. 22 
Eq. 22 uses ClogP77 to describe the liquid-liquid interaction in the solvation process 
and the fitted coefficients b i to study the cohesive energy caused by each fragment in 
the solid state. Thus, the solubility value of a fragment could be calculated, which 
was the sum of the fragmental contribution to lipophilicity and to crystal packing. The 
solubility values of fragments are listed in the appendix and used later for the 
solubility prediction of external data described in the literature. (chapter 4.3.4.1) 
Aqueous Solubility Prediction of Drug-like Compounds 
- 105 - 
0
2
4
6
8
10
0 1 2 3 4 5 6 7 8 9 10 11
Y
V
ar
P
S
(lo
g1
_S
0_
ne
w
)
YPredPS[3](log1_S0_new)
y=1.005*x-0.02675
R2=0.8325
Training data set (n = 1515)
Test data set (n = 958)
Log1/S0 (pred)
Lo
g1
/S
0
(e
xp
)
Y
V
ar
P
S
(lo
g1
_S
0_
ne
w
)
Lo
g1
/S
0
(e
xp
)
 
Figure 41:  The final solubility model generated with 1515 compounds (blue) in the training data set 
and tested with 958 (red) in the test data set. 
Figure 41 shows the solubility of most compounds is predicted within an error of one 
log unit. The standard error of the predicted solubilities is 0.42 log units. The 
correctness of the solubility classification are listed in Table 23. More than 50% 
compounds in each solubility range were correctly classified. 
Solubility S (µg/mL) Nrcompounds %correct classification 
low S <= 10 944 66% 
medium 10 < S <= 100 992 69% 
high S > 100 537 51% 
Table 23:  The correctness of solubility classification for 2473 compounds with the model described 
in Eq. 22. 
253 neutral drugs used in the chapter 4.1.1.4 to test the program SRC WsKow91 
were also used to test the newly developed prediction tool. 
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Figure 42:  Solubility prediction of 253 neutral drugs. a) Residue diagram for prediction with SRC 
WsKow91; b) residue diagram for prediction with the newly developed tool; c) experimental 
versus predicted solubility with SRC WsKow91; d) experimental versus predicted solubility 
with the newly developed tool. 
In comparison to the program SRC WsKow91, the residues of most compounds 
predicted with the newly developed tool were much lower. Most lay within 1 log unit 
and no single residual was higher than 2 log units. (Figure 42a and b) Additionally, 
the correlation between predicted and experimental solubility was much better when 
using the newly developed tool compares to the program SRC WsKow91. (Figure 42c 
and d) 
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467 organic compounds, for which the fragments were present in the newly 
developed fragmental database were selected from AQUASOL67 database and used 
as test data set for the solubility prediction. 
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Figure 43:  Solubility prediction of 467 organic compounds in AQUASOL database. a) Solubility 
prediction with SRC WsKow91; b) solubility prediction with the newly developed tool. The 
blue colored compounds are 1515 drugs used as training data set for the prediction tool. 
The red colored are 467 organic compounds used as test data set. 
In comparison to the program SRC WsKow91 (Figure 43a), the solubility of these 467 
compounds were not well predicted with the newly developed prediction tool, resp. 
two separate data sets could be observed in the Figure 43b. 
In order to explain the differences between drug-like compounds and 467 organic 
compounds from the AQUASOL67 database, PCA analysis was performed for the 
related data sets. Five components were calculated for PCA and its first three 
component (t1 -t3) described 78.1% of the x-space. 
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Figure 44:  PCA analysis for 467 organic compounds in the AQUASOL67 database (blue) and 1515 
drug-like compounds (red). a) PCA score plot; b) PCA loading plot. 
The 467 organic compounds in AQUASOL67 database and 1515 drug-like 
compounds were detected in PCA analysis as two separate clusters. (Figure 44a) 
The dominating descriptors for this separation were %aromatic atoms, %C and 
molecular weight. (Figure 44b) A comparison of the descriptors is shown in Figure 45. 
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Figure 45:  Comparing the properties of 467 organic and 1515 drug-like compounds. 
Figure 45 shows drug-like compounds contain mostly aromatic atoms and have 
higher molecular weight. Additionally, a more compact crystal packing can always be 
observed for drug-like compounds, because of the intermolecular hydrogen bonding. 
In contrast to the drug-like compounds, 35% of 467 organic compounds used here 
contain only aliphatic carbons and such molecules are held together in the crystal 
state through the van der Waals interactions. Therefore, the contribution of an 
aliphatic carbon atom to the solubility is different for simple organic compounds, in 
comparison to drug-like molecules. Hence, the application of the newly generated 
solubility prediction model is directed to the prediction of solubility of drug-like 
compounds. 
As mentioned in chapter 4.1.1.5, among the 1770 compounds in the AQUASOL67 
database, there are 206 drug-like, resp. 11.6%, which are not part of the third data 
set. The model in Figure 46 was generated for 206 drug-like compounds in the 
AQUASOL67 database together with 2473 reference compounds by including the 
definition of 58 new fragmental constants for the 206 compounds from the 
AQUASOL67 database. 
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Figure 46:  Solubility prediction for 206 drug-like compounds in AQUASOL67 database and 2473 
reference compounds. 
Figure 46 shows that the solubilities of 206 drug-like compounds from the 
AQUASOL67 database are much higher than the reference compounds. Nevertheless, 
the correlation between the predicted and experimental value (Figure 46) shows the 
arrangement of these 206 AQUASOL67 drug-like compounds is in line with the red 
colored reference compounds. 
4.3.4.1 Solubility prediction for external data described in the 
literature 
Several literature studies88,92-95 on physicochemical characterization of drug-like 
congeneric series were found. The described solubility values were used as external 
validation data sets to test the predictive power of the newly developed solubility 
prediction tool. 
The derived fragment related coefficients were applied to predict the solubility of 
external congeneric series. Two methods were evaluated to derive solubilities for 
compounds with similar structures: 
1. The experimental solubility of a compound in the congeneric series was 
taken as a starting point. The scaffold solubility value of this compound was 
calculated by subtracting the solubility values of substituents from the 
compound’s experimental solubility value. The required solubility prediction 
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value of any other compound was a result of the calculated value of the 
scaffold and the solubility values of substituents derived from the generated 
solubility model. 
2. The scaffold solubility value would be first calculated for each compound in 
the congeneric series, by subtracting the solubility values of substituents 
from the compound’s experimental solubility value. Finally, the mean value 
of the scaffold was assigned to all compounds. The predicted solubility value 
of each compound resulted then from the mean value of the scaffold and its 
substituents’ fragmental solubility values. 
The predictive power of the newly developed solubility prediction tool was directly 
compared with the commercially available tool, WaterFrag96 developed by Meylan. 
4.3.4.1.1 Validation with the external data set 1 
Goosen88 measured the solubility of thalidomide and its N-alkyl analogues in water at 
pH = 6.4 and 25°C. Because the fragmental value of AC(=O)[NH]C(=O)A in 
thalidomide was not available, N-methyl-thalidomide was taken as the starting point 
for the solubility calculation following method 1. 
N
O
O
N
O
O R1  
Figure 47:  The scaffold of thalidomide derivates. 
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Name Substituent R1 Sexp (µg/mL) MW Log1/S0(exp) Log1/S0(pred)  Log1/S0(pred WaterFrag)  
Thalidomide 
H  
52.1 258 3.69  1.34 
N-Methyl 
thalidomide* CH3  
275.9 272 2.99 2.99 1.83 
N-Propyl 
thalidomide 
CH3  
57.3 300 3.72 3.08 2.9 
N-Pentyl 
thalidomide 
CH3  
6.54 328 4.7 3.16 4 
Table 24:  The solubility data of thalidomide and its N-alkyl analogues88. *: Compound was taken as 
starting point for the prediction with the newly developed solubility tool. 
Table 24 shows the solubility decrement caused by lengthening the chain length is 
correctly predicted using both programs, resp. the newly developed tool and the 
program WaterFrag96 developed by Meylan. However, the decrement caused by one 
aliphatic carbon was correctly predicted by WaterFrag96 (Dlog1/S0(CH3) = 0.5 log units), 
but not by the newly developed tool (D log1/S0(CH3) = 0.05 log units). Databases 
containing drug-like compounds were scanned to find similar examples. Such 
examples should be compounds with experimental solubilities and struc tures 
containing the fragment *C(=O)N(*)C(=O)* with corresponding modification on the N-
alkyl chains. However, the glutarimide ring with long N-alkyl chain is considered as 
instable. Therefore, it is difficult to evaluate the quality of the prediction by only using 
these four compounds of Goosen88. Additionally, it is known, that the program 
WaterFrag96 is based on the same fragmental database as the program Kowwin97 
and the increment of lipophilicity caused by a methylene group has a value of 0.5 log 
units. Thus, it can be assumed that the solubility coefficient of the methylene group in 
the WaterFrag96 is derived from its lipophilicity value. Furthermore, the shift of 
solubility caused by one aliphatic carbon is not always about 0.5 log units. It can vary 
between 0.01 and 1.09 log units, which depends on the structural environment of the 
methylene group, as collected in Table 25. 
  
Name Structure Log1/S0 Name Structure Log1/S0 
Shift of log1/S0 caused 
by one methylene group 
compound 15 
N
H
O
Scaffold1
 
4.56 compound 16 
N
H
O
Scaffold1
 
4.68 0.12 
compound 17 
N
H
O
Scaffold2
 
4.34 compound 18 
N
H
O
Scaffold2
 
4.48 0.14 
compound 19 
O
Scaffold3
 
5.55 compound 20 
O
Scaffold3
 
5.09 -0.46 
compound 21 
S
O
O
Scaffold4
 
5.64 compound 22 
S
O
O
Scaffold4
 
4.95 -0.69 
compound 23 
N
O
Scaffold5
 
4.66 compound 24 
N
O
Scaffold5
 
4.93 0.27 
compound 25 
NScaffold6
 
4.77 compound 26 
NScaffold6
 
5.03 0.26 
compound 27 
N
O
Cl
Scaffold7
 
5.53 compound 28 
N
O
Cl
Scaffold7
 
5.68 0.15 
  
compound 29 N
Scaffold8
 
7.87 compound 30 N
Scaffold8
 
7.61 -0.26 
compound 31 
N
H
S
N
S
N
HO
O
Scaffold9a
Scaffold9b
 
4.56 compound 32 
S
N
HO
O
N
H
S
N
Scaffold9a
Scaffold9b
 
5.65 1.09 
compound 33 
S
N
HO
O
N
S
N
H
Scaffold9a
Scaffold9b
 
5.36 compound 34 N
H
S
N
S
N
HO
O
Scaffold9a
Scaffold9b
 
5.66 0.3 
compound 35 N
O
OH
Scaffold10
 
3.44 compound 36 N
O
OH
Scaffold10
 
3.53 0.09 
compound 37 
OHScaffold11
 
4.51 compound 38 
OHScaffold11
 
4.16 -0.35 
compound 39 N
H N
Scaffold12
 
3.90 compound 40 N NScaffold12
 
4.78 0.88 
compound 41 
OHScaffold13
 
4.42 compound 42 
OHScaffold13
 
4.78 0.36 
compound 43 
NH2Scaffold14
 
7.04 compound 44 
NH2Scaffold14
 
6.31 -0.37 
Table 25:  Example for the solubility shift caused by adding a methylene group to compounds with the same scaffold. The compounds listed in the 
same raw have the same scaffold, which is signified with the number of the scaffold. 
  
Name Structure Log1/S0 Name Structure Log1/S0 
compound 45 N
NH
O
O
Scaffold15
 
4.88 compound 46 N
NH
O
O
Scaffold15
 
5.29 
compound 47 
N
NH
O
O
CH3
Scaffold15  
5.11 compound 48 
N
NH
O
O
CH3
Scaffold15  
5.12 
compound 49 
N
NH
O
O
Scaffold15  
5.28    
compound 50 
N
NH
O
O
CH3
Scaffold15
 
4.76    
Table 26:  Collection of six compounds with the same scaffold and comparison of changes in their solubility caused by adding a methylene group on 
two different substituent positions. 
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Table 25 shows, that adding a methylene group can increase the solubility in some 
cases. Such phenomenon happens frequently, when the crystal packing is changed. 
(Chapter 4.3.2) Additionally, Table 26 shows that it is not easy to find a general rule 
for describing the influence of a methylene group on the solubility, because the 
solubility shift can be different, even when the addition of the methylene group occurs 
at the same position. 
4.3.4.1.2 Validation with the external data set 2 
Bavetsias92 measured the solubility of CB30865 analogues at pH = 7.4 in 10 mM 
potassium dihydrogen phosphate containing 150 mM sodium chloride. 
N
N
O
R1
Cl
N
O
N
H
N
 
Figure 48:  The scaffold of CB30865 analogues. 
pKa 
Nr Substituent 
pKa1 pKa2 
MW S (µM) Log1/S0 Log1/S0 (pred) Log1/S0 (WaterFrag) 
1* 
N
N
Me  
4.65 7.86 584 146 4.49 4.49 2.99 
2 
O
N
 
4.65  571 2 5.79 4.27 3.36 
3 
N
N
E t  
4.65 7.16 598 286 3.77 4.53 3.53 
4 
N
N
OH  
4.65 7.16 614 75 4.36 3.95 1.76 
5 N
N
 
4.65  646 5 5.39 5.10 6.85 
6 N
OH  
4.65  585 0.5 6.39 4.10 3.18 
Table 27:  The solubility of CB30865 analogues92. *: The compound was taken as starting point for 
the prediction with the newly developed solubility tool. 
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Figure 49:  Comparison of solubility of CB30865 analogues92 predicted with the new solubility tool and 
WaterFrag. 
pKa calculated by ACD78 was used to consider the pH dependence of solubility. For 
the 6 compounds in Table 27, the solubility prediction results achieved by the newly 
developed tool were much better in comparison to WaterFrag96. 
4.3.4.1.3 Validation with the external data set 3 
Edwards94 measured the solubility of pyridopyrimidine trifluoromethyl ketones in 0.01 
M sodium phosphate buffer at pH = 7.4. 
N
N
H
N
O
O
O
N
H
O
O
F
F
F
R1
 
Figure 50:  The scaffold of pyridopyrimidine trifluoromethyl ketones94. 
Aqueous Solubility Prediction of Drug-like Compounds 
- 118 - 
Nr Substituent pKa MW S (mg/mL) Log1/S0 Log1/S0 (pred ) 
Log1/S0 (pred 
WaterFrag) 
1 H  464 0.22 3.32  2.82 
2* CH3  478 0.044 4.03 4.03 3.31 
3 
CH
3
O  
 584 0.23 3.40 4.35 6.08 
4 
NH2
O  
 521 0.13 3.60 3.65 1.81 
5 
N
H
O  
 535 0.1 3.73 3.34 1.96 
6 N
 
 507 0.32 3.20  1.67 
7 
O
O  
 538 0.42 3.11 4.27 2.36 
8 CH3 O  
 536 0.008 4.83 3.80 3.65 
9 
O
N
 
7.04 577 0.30 3.44 3.74 2.15 
Table 28:  The solubility of pyridopyrimidine trifluoromethyl ketones94. *: The compound was taken as 
starting point for the prediction with the newly developed solubility tool. 
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Figure 51:  Comparison of solubility of pyridopyrimidine trifluoromethyl ketones94 predicted with the 
new solubility tool and WaterFrag. 
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Because of the lack of the fragments, the solubility of compounds 1 and 6 could not 
be predicted. The solubility prediction results for the remaining 7 compounds using 
the newly developed tool was much better in comparison to WaterFrag96. 
4.3.4.1.4 Validation with the external data set 4 
Bernstein95 measured the solubility of 3-amino-6-phenylpyridin-2-one trifluroromethyl 
ketones in 0.01 M sodium phosphate buffer at pH = 7.4. 
N
O
N
H
N
H
O
O
R1
FF
F
 
Figure 52:  The scaffold of 3-amino-6-phenylpyridin-2-one trifluoromethyl ketones95. 
Nr Substituent pKa MW LogP95 (exp) S (µg/mL) Log1/S0 Log1/S0 (pred 
Log1/S0 (pred 
WaterFrag) 
1* O
O
 
 529  1.8 5.47 5.47 4.22 
2 
N
N
H
O
 
5.46 529 2.16 140 3.58 4.53 1.34 
3 
N
N
H
O
 
5.03 529 2.84 430 3.09 4.53 1.34 
4 
N
N
H
O
 
4.88 529 2.15 300 3.25 4.53 1.34 
5 
O
O
OH
O  
4.1 573 0.84 2600 5.64 6.53 4.37 
6 O
OOH
O
 
4.09 573  1570 5.87 6.53 4.37 
7 O
OH
O
 
4.17 557 0.35 2500 5.58 5.30 3.53 
8 
O
OH
O  
4.13 557  900 6.06 5.30 3.53 
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9 
O
OH O  
3.85 557 1.14 2500 5.90 5.30 2.87 
10 
N
O
O
 
4.65 530 2.41 16 4.52 5.30 1.96 
11 
N
O
O
 
4.65 530 1.91 2.1 5.42 5.30 1.96 
12 
N
O
O
 
4.65 558 2.38 8.5 4.82 5.39 3.01 
13 
CH3
O
 
 437 1.78 92 3.68 3.94 0.95 
14 
O
N
O
 
5.43 522 2.00 23 4.36 3.60 -0.28 
15 H
O
 
 423 1.84 220 3.28 4.18 0.38 
16 N
O
O
O
 
 534 0.96 3100 2.24  0.34 
17 CH3 O
O
O
 
 481  840 2.76 4.29 0.37 
18 H 3.49 395 1.74 490 2.91 3.78 0.55 
19 CH3CH2 3.86 423 2.37 280 3.18 4.04 1.24 
20 S
OO
CH3
 
8 473 1.77 4100 2.16 1.72 0.67 
21 
S
OO
F F
F
 
8 527 0.94 940 2.85 1.46 1.87 
22 S
OO
N
H
CH3
 
8 488 1.79 1730 2.45  0.62 
23 
S
OO
N
H
 
8 564 2.57 21 4.42  3.06 
24 
S
OO
N
 
5 564  100 3.85 1.95 1.38 
25 
S
OO
 
8 535 2.53 180 3.57 4.20 3.80 
Table 29:  The solubility of 3-amino-6-phenylpyridin-2-one trifluoromethyl ketones95. *: The 
compound was taken as starting point for the prediction with the newly developed 
solubility tool. 
Aqueous Solubility Prediction of Drug-like Compounds 
- 121 - 
-1
0
1
2
3
4
5
6
7
-1 0 1 2 3 4 5 6 7
Log1/S0 (exp)
L
o
g
1/
S
0 
(p
re
d
)
New Solubility Tool WaterFrag
 
Figure 53:  Comparison of solubility of 3-amino-6-phenylpyridin-2-one trifluoromethyl ketones95 
predicted with the new solubility tool and WaterFrag. 
Because of the lack of the fragments, the solubility of compounds 16, 22 and 23 
could not be predicted. The solubility prediction results for the rest of 22 compounds 
were much better with the newly developed tool than with WaterFrag96. Table 29 
shows the solubility difference caused by diverse substituent positions on the 
aromatic ring, resp. ortho, meta and para, can be 0.5 log units. Unfortunately, such 
position caused solubility difference can not be correctly predicted in the current form 
of the newly developed tool or program WaterFrag96. 
4.3.4.2  Structure based solubility rules 
The contribution of fragments to solubility were derived as a result of the weighting of 
the structural fragments used in the new solubility prediction model. Thus, 460 
structure based solubility rules were derived and listed in the appendix. Furthermore, 
molecular properties important for the solubility enhancement can be identified by 
inspection of the structure based solubility rules. A small section from the appendix is 
taken here as example to visualize the influence of small structural changes on 
intrinsic solubility as shown in Figure 54. 
Aqueous Solubility Prediction of Drug-like Compounds 
- 122 - 
O
O H
O
OH
N
H N
NH2 NH2
N
H
O N
H
O
Intrinsic Solubility Enhancing Fragments
N
N
N
N
 
Figure 54:  Examples for intrinsic solubility enhancing fragments. 
In case both hexagonal rings have similar pKa values, the compounds with aliphatic 
fragments are more soluble than those with aromatic ones, e.g. 
O
OH
O
OHhas higher intrinsic solubility than 
 
Furthermore, strong basic and acidic fragments provide lower intrinsic solubilities 
than similar neutral ones, because of the formation of intermolecular hydrogen bonds, 
e.g. 
NH2 NH2
has higher intrinsic solubility than 
 
Fragments with high polar surface are solubility enhancing, e.g. 
N N
N
Increasing intrinsic solubility  
Aqueous Solubility Prediction of Drug-like Compounds 
- 123 - 
Moreover, fragments with high dipole moment are more soluble than fragments with 
low dipole moment. e.g. 
N
N
N
N
Increasing intrinsic solubility  
In conclusion, property-based solubility rules were deduced by comparison of the 
influence of different rings on the solubility. They partly reflect the already existing 
knowledge in that field as to summarized: 
1 Compounds containing aliphatic fragments are more soluble than aromatic 
ones. 
2 Dipole moment enhances solubility. 
3 Compounds containing polar fragments are more soluble than non polar 
ones. 
4 Compounds containing strong basic and acid fragments have lower intrinsic 
solubility than neutral ones. 
In contrast to the property based solubility rules, structure based solubility rules can 
be more conveniently used by medicinal chemist as a guideline to improve the 
structures of leads to achieve higher solubility. Hence, a more diverse data set 
should be collected in the near future to optimize the developed solubility model and 
to extend the structural based rules by addition of further structural fragments. 
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4.3.5 The impact of solid state on solubility 
Aqueous solubility of a compound is governed by three major factors98: 
· intermolecular interactions in the crystal lattice 
· the difference between the solute-water adhesive interaction and the sum 
of the solute-solute and water-water interactions 
· the entropy of mixing (solute/solvent) 
In order to study the impact of solid state on solubility, two data sets containing 
compounds with measured 3D crystal structures and melting points were collected. 
(chapter 4.2.1.1) 
Melting point is considered as an important parameter for assessing the cohesive 
energy of solid state. The relationship between melting point and the formation of 
intermolecular hydrogen bonds was confirmed by the descriptors used in the 
prediction of melting point for the second data set. The number of hydrogen donors 
was identified as the most important descriptor for the prediction of melting point. 
Furthermore, the influence of solid state properties on solubility was confirmed by 
solubility models for the first and second data set, because the number of hydrogen 
donors, melting point and lipophilicity belonged to the most important parameters. 
(Eq. 20 and Eq. 21) The VIP plots in the related solubility studies identified 
lipophilicity as a more important descriptor in the prediction of solubility than the 
number of hydrogen bonds or melting points. This leads to the conclusion that the 
solubility of drug-like compounds depends more on the solvation process than the 
cohesive energy in solid state. 
In order to evaluate the extent of the influence of solid state on solubility, polymorphs 
were evaluated. Differences in the solubilities of polymorphic forms can be assumed 
to be only dependent on differences in the crystal packing. 
Pudipeddi27 collected a solubility data set of 72 compounds with diverse polymorphs. 
2 to 3 fold differences in solubilities were observed for most of the collected cases. 
Larger differences were described for premafloxacin28 (~30 fold), codeine29 (~13 fold) 
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and cyclopenthiazide30 (~4 fold). According  to those results, it can be assumed that 
differences in solubilities which are based on different crystal packings and resulting 
in polymorphs are usually low and are often in the range of the experimental error of 
the solubility measurements. 
Polymorphs can be divided into two categories, resp. enantiotropic and monotropic. 
The differences between both categories are described in Table 30. 
Enantiotropic Monotropic 
Transition temperature < melting temperature of I Transition temperature > melting temperature of I 
I is stable above transition temperature; II is stable below 
transition temperature 
I always stable 
Transition reversible Transition irreversible 
Solubility of I higher than II below transition temperature; 
solubility of II higher above transition temperature 
Solubility of I always lower than II 
Transition from II to I endothermic 
DHIf < DHIIf 
Transition from II to I exothermic 
DHIf > DHIIf 
Density I < density II Density I > density II 
Table 30:  Thermodynamic rules for enantiotopic and monotropic phase transitions99. I is the higher 
melting form. 
Enantiotropic polymorphs can be interconverted below the melting point of each 
polymorph, because different enantiotopic forms are stable under different conditions, 
while monotropic polymorphs behave differently. Thus, for a monotropic polymorphic 
pair, only one thermodynamically stable form under all attainable conditions does 
exist. However, the unstable form of a monotropic polymorphic pair can still be useful, 
because the activation energy for the conversion to the stable form is high, and under 
this situation, the meta stable compound can be formed. Table 31 shows 
characteristic properties of known polymorphs collected from different literature 
sources30,100-106. 
  
Name 
Polymorphic 
forms  
S 
(µg/mL) 
Solution 
Melting 
point (°C) 
Transformation by heating Comment 
I 34.7 238  
II 61.80 225  Cyclopenthiazide30 
III 17.15 
Water 
 III I (238°C)
181°C
 
Forms I and II showed only a single melting point at 238 
and 225°C. Form III melts at 181°C and then 
recrystallizes to form I. 
I 3230  
II   Premafloxacin100 
III 140 
Ethyl acetate 
198-202 
I II III
140-150°C 165-180°C
ExothermEndotherm  
 
I 1240 164  
MK571101 
II 2400 
Methyl ethyl 
ketone 152  
No conversion is observed between form I and II. 
I 600   
Auranofin102 
II 1300 
25% 
polyethylene 
glycol 200 
389 
I II (389°C)
385°C
  
I 543   
Seratrodast103 
II 817 
50 mM 
phosphate 
buffer at pH=8 
 
I II
83.4°C
  
A 2040   
Acetazolamide103 
B 2280 
50 mM 
phosphate 
buffer at pH=8 
 
A B
78.4°C
  
I 11560   
Carbamazepine103 
III 9680 
50 mM 
phosphate 
buffer at pH=8 
 
III I
73°C
  
a 576 157  No conversion is observed between form a and b . 
Indomethacin103 
b 432 
50 mM 
phosphate 
buffer at pH=8 
163   
Mefenamic acid104 I 6090   
 II 7930 
50 mM 
phosphate 
buffer at pH=8 
 
I II
89°C
  
I 677   
Sulfathiazole104 
II 1118 
50 mM 
phosphate 
buffer at pH=8 
 
I II
112.6°C
  
  
I 160   
Proscar105 
II 59 
Water at 25 
°C  II I
165°C
  
I 205-211 91.7 mg%  
Sulfuno106 
II  
Water at pH = 
3.8 T = 20 °C 84.6 mg% II I
188-195°C
  
I 172-182 8.9 mg%  
Tromexan106 
II 153-160 
Water at pH = 
3.8 T = 20 °C 15.3 mg%  
No automatic conversion is observed between form I and 
form II 
Table 31:  Polymorphs with their corresponding transition temperatures. The enantiotropic polymorphs are the I and III forms of cyclopenthiazide, the I 
and II forms of premafloxacin, the I and II forms of auranofin, the I and II forms of seratrodast, the A and B forms of acetazolamide, the III 
and I forms of carbamazepine, the I and II forms of mefenamic acid, the I and II forms of sulfathiazole, the I and II forms of proscar, the I 
and II forms of sulfuno. The monotropic polymorphs are the I and II forms of cyclopenthiazide, the II and III forms of premafloxacin, the I 
and II forms of MK571, the a and b forms of indomethacin and the I and II forms of tromexan. 
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Most polymorphs in Table 31 are enantiotropic, which crystallize according to the 
empirical Ostwald’s law in stages107. Take cyclopenthiazide as an example. The form 
I and III of cyclopenthiazide are enantiotropic. By heating, form III transforms to form I 
before it melts. Thus, 181°C is considered as the conversion temperature of form III, 
which is lower than the melting point of form I (238°C). Usually, the higher the melting 
point, the lower the solubility. However, form I has a higher solubility value than form 
III, although its melting point is high. The higher solubility value of form I can be 
explained by measuring the reaction energy required by the transformation. From 
form III to form I, heating is needed for the conversion. Therefore, form III is the most 
stable and the least soluble form at room temperature. However, the melting point of 
form III is probably so high, that is not measurable. Therefore, in case of enantiotopic 
forms, no direct comparison of melting point and solubility can be performed for these 
two related polymorphic forms. 
The I and II form of cyclopenthiazide are monotropic. Both of them occupy a single 
melting point at 238 and 225°C. Thus, no automatic conversion can be expected 
between these two related forms. Furthermore, relationship is observed between 
melting points and solubilities of these two monotropic forms. The most stable form, 
resp. form I has a higher melting point and lower solubility than the less stable form, 
resp. form II. 
Beside the diazepam derivates described in the chapter 4.2.1.2.3.1 and the 
sulfadiazine in the chapter 4.3.2, the halogen analogues of deoxyuridine derivates in 
the first data set can be used as an additional example for studying the influence of 
solid state on solubility. 
N
N
O
O
R1H
O
OHOH  
Figure 55:  The scaffold of deoxyuridine derivates. 
  
R1 Name 2D Structure 3D Crystal Structure MW ClogP LogP89 (exp) MP (°C) pKa S (µg/mL) pH Log1/S0 
H 2’-deoxyuridine   228 -1.884 -1.467 165-167 9.16 1695276 6.5 -0.87 
CH3 thymidine 
N
N
O
O
CH3H
O
OO
H
H
O
N
H
 
 
242 -1.385 -1.177 186-188 9.55 64298 6.5 0.58 
C2H5 
5-ethyl-2’-
deoxyuridine N
N
O
O
H
O
O O
H
N
H
H
N
N
O
O
H
O
OH O
HO
O
  
256 -0.856 -0.646 152-153 9.57 71750 6.6 0.55 
CF3 
a,a,a-
trifluorothymidine 
  296 -0.413 0.009 178-180 7.5 39128 6.3 0.91 
  
F 
5-fluoro-2’-
deoxyuridine 
N
N
O
O
FH
O
OO
H
H
O
N
H
 
 
246 -1.405 -1.2 148-150 7.42 502278 5.5 -0.3 
Cl 
5-chloro-2’-
deoxyuridine 
N
N
O
O
ClH
O
OO
H
H
O
N
H
 
 
262 -0.835 -0.937 176-177 7.74 58862 6.3 0.66 
Br 
5-bromo-2’-
deoxyuridine 
N
N
O
O
BrH
O
OO
H
H
O
N
H
 
 
307 -0.685 -0.572 191-194 7.78 14752 6.5 1.34 
  
I 
5-iodo-2’-
deoxyuridine 
N
N
OI
O
O
O O
H
H
H
N
N
OI
O
O
O O
H
H
H
O
H
N O
H
N
 
 
354 -0.425 -0.282 155-180 8.09 1900 6.5 2.28 
Table 32:  The influence of halogen atoms and crystal lattice on solubility for selected compounds from data set 1. 
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Table 32 shows that the melting points of the halogen analogues increase with 
ascending atomic weights, until iodine atom is added to the scaffold. The observed 
reduction of melting point by substituting the bromine with iodine atom can be 
explained by comparing the crystal packing of halogen analogues with methyl and 
ethyl derivates. The methyl derivate occupies the same conformational space as F, 
Cl and Br derivates. The uracil hydrogen group forms an intermolecular hydrogen 
bond with the hydroxyl group on the furan ring. Furthermore, there are differences in 
size between the ethyl and methyl moiety. Substituting the methyl with an ethyl group, 
crystal packing with lower density is possible; resp. the uracil hydrogen group forms 
an intermolecular hydrogen bond with the methoxyl group, but not with the hydroxyl 
moiety. The lower melting point of ethyl derivate results in the similar solubility values 
for ethyl and methyl derivates, although the lipophilicity and molecular weight of the 
ethyl derivate is higher. Therefore, melting point is an important parameter for 
assessing the influence of crystal cohesive energy on solubility. Within a series of 
compounds with similar structures, the influence of solid state on solubility can be 
especially high, when modification of substituents causes a change of crystal packing. 
An external data set of (4S)-7-(4-amino-2-substituted-pyrrolidin-1-yl)quinolone-3-
carboxylic acids93 is used in the following to demonstrate the impact of solid state on 
solubility. 
X N
O
OH
O
R2
F
F
R1
 
Figure 56:  The scaffold of (4S)-7-(4-amino-2-substituted-pyrrolidin-1-yl)quinolone-3-carboxylic acids93. 
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Substituent pKa 
Nr 
R1 X R2 pKa1 pKa2 pKa3 
MW logP 
S 
(µg/mL) 
Log1/S0 
MP 
(°C) 
1 
N
NH2  
N F 4 8  404 -0.46 8 4.80  
2 N
OH
NH2  
CH F 4 8  433 -0.98 60 3.96 
214-
21793 
3 N
OH
NH
2  
CH F 4 8  433  60 3.96 >24093 
4* 
N
N
NH2  
CH F 4 8 9 486 -0.56 680 3.55 24593 
5 N
CH3
NH2  
CH F 4 8  417 0.085 
53 3.99 
206-
21093 
6 N
CH3
NH2  
CH F 4 8  417 0.03 182 3.46 >15093 
7 N
CH3
NH2  
N F 4 8  418 -0.2 
150 3.54 
231-
23493 
8 N
CH3
NH2  
N F 4 8  418 -0.11 340 3.19 
294-
29693 
Table 33:  The solubility of (4S)-7-(4-amino-2-substituted-pyrrolidin-1-yl)quinolone-3-carboxylic 
acids93 measured using 0.05 M phosphate buffer at pH = 7.4. 
3.34 fold 
2.26 fold 
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Figure 57:  The relationship between melting points and solubilities of (4S)-7-(4-amino-2-substituted-
pyrrolidin-1-yl)quinolone-3-carboxylic acids93. 
Table 33 shows, although melting point is an important parameter for solubility, it can 
not be used independently. For example, no direct correlation is observed between 
solubilities and melting points in this series. (Figure 57) Furthermore, the solubility of 
compound 8 is higher than compound 2, in spite of its higher melting point. 
Nevertheless, melting point is still an useful parameter in describing solubility 
variation. Table 33 shows, that the solubility to a certain degree is dependent on the 
stereo chemistry. The higher melting points of stereoisomers 7 and 8 lead to minor 
improvement in their solubility in comparison to stereoisomers 5 and 6. 
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Figure 58:  a) The relationship between solubility and lipophilicity; b) the relationship between solubility 
and molecular weight of (4S)-7-(4-amino-2-substituted-pyrrolidin-1-yl)quinolone-3-
carboxylic acids93. 
In case of no remarkable relationship between lipophilicity, molecular weight and 
solubility (Figure 58), fragmental based tool is often considered as an useful method 
to predict the solubility. 
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Nr Log1/S0 
(exp) 
Log1/S0 
(pred) 
Log1/S0 
(pred 
WaterFrag) 
1 4.80 3.31 0.27 
2 3.96 2.95 1.28 
3 3.96 2.95 1.28 
4 3.55 3.55 2.62 
5 3.99 3.52 3.05 
6 3.46 3.52 3.05 
7 3.54 3.35 0.79 
8 3.19 3.35 0.79 
0
1
2
3
4
5
6
0 1 2 3 4 5 6
Log1/S0 (exp)
Lo
g1
/S
0 
(p
re
d)
New Solubility Tool WaterFrag
 
Table 34:  Comparison of the solubility of (4S)-7-(4-amino-2-substituted-pyrrolidin-1-yl)quinolone-3-
carboxylic acids93 predicted with the newly developed solubility tool and WaterFrag. 
Table 34 shows, that the newly developed solubility tool can not differentiate between 
the solubility of stereoisomers, because it is based on 2D structures. (e.g. compound 
5 and 6, compound 7 and 8). Nevertheless, the tool developed in this study shows 
significant better solubility prediction results than the commercial product 
WaterFrag96 for all eight compounds listed in Table 34. 
In conclusion, the impact of solid state on solubility was studied by collection of 
compounds with diverse polymorphic forms, measured 3D crystal structures and 
melting points. When polymorphs are monotropic, a direct comparison of melting 
point and solubility could be performed and crystal state related information was 
identified as an important factor for solubility. However, in comparison with 
lipophilicity, the influence of crystal lattice on solubility is restricted. Solubility 
differences caused by diverse crystal packing of polymorphs are usually 2 to 3 fold, 
which is in the range of the experimental error of the solubility measurements. Within 
a series of compounds with similar structures, the often described rules that the 
higher melting point related to lower solubility can not be always confirmed. 
Nevertheless, the influence of solid state on solubility can be especially high, when 
modification of substituents cause a change of crystal packing. Therefore, melting 
point is an useful parameter in describing solubility variation. Furthermore, in case, 
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when solubility values can not be reasonably predicted using properties like 
lipophilicity, molecular weight and crystal state related information, fragmental based 
solubility prediction tool can be considered as an alternative. Thus, the influence of 
substituents on solubility was carefully studied using high quality solubility data of 
drug-like compounds in congeneric series. A general solubility model of high 
accuracy was developed, which showed significantly higher predictive power for 
drug-like compounds in comparison to commercially available tools. The derived 
fragment contributions to solubility can guide the decision processes in the synthesis 
of more soluble drug candidates. 
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5 CONCLUSIONS AND OUTLOOK 
Aqueous solubility of drug-like compounds was studied from two aspects, in vitro and 
in silico. A new crystallization method based on saturated solution was developed, 
which avoids disadvantages of usual methods such as formation of amorphous 
materials from supersaturation. The invented method was applied for patent EU 
05018750.9, in order to secure the achieved intellectual property for future 
pharmaceutical application. The experimental results showed crystalline forms of 
weak acids or bases could be more easily obtained using the newly developed 
crystallization method. Compounds with high tendency to form amorphous materials 
usually had higher HT solubility values than equilibrium solubilities. In the 
development of improved in silico solubility models, lipophilicity was confirmed as the 
major driving factor and crystal information related descriptors as the second 
important factor for solubility. Reasons for the limited precision of commercial 
solubility prediction tools were identified. A general solubility model of high accuracy 
was obtained for drug-like compounds in congeneric series when lipophilicity was 
used as descriptor in combination with the structural fragments. Rules were derived 
from the prediction models of solubility which could be used by chemists or interested 
scientists as a rough guideline on the contribution of structural fragments on solubility: 
Aliphatic and polar fragments with high dipole moments are always considered as 
solubility enhancing. Strong acids and bases usually have lower intrinsic solubility 
than neutral compounds. In summary, an improved solubility prediction method for 
congeneric series was developed using high quality solubility results of drugs and 
drug precursors as input parameter. The derived model overcomes difficulties of 
commercially available solubility prediction tools by focusing on structurally related 
series and showed a much higher predictive power for drug-like compounds in 
comparison to commercially available tools. 
The theoretical solubility model obtained in this thesis has an average error of ± 0.42 
log units. Practical solubility measurements showed average error of ± 0.143 log 
units. Thus the newly developed model meets well or exceeds the precision of 
commercially available prediction tools which have a typical deviation of about 1 to 2 
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log units66. Hence the new model can be smoothly used for aqueous solubility 
predictions of drug-like compounds in congeneric series and for evaluating the 
substituental effect on the solubility. However, there is still room for improvement and 
there are a number of different options to further improve the success of the 
prediction. Firstly, the predictive power could be enhanced by using the measured 
ionization constant to consider the pH dependence of solubility. Secondly, 
incorporating information reflecting solid state, e.g. crystal structure and density, 
melting point and information about polymorphic forms, would result in better 
solubility predictions. Thirdly, the model flexibly allows extending the initial data set 
by addition of further structural fragments in order to enhance the predictive power. 
Fourthly, solubility predictions could be extended from aqueous to other solvent 
systems, when high quality data in such systems are available. Solubility in other 
solvent systems is considered as important as aqueous solubility, because different 
solvent and solvent mixtures are frequently used in the pharmaceutical industry for 
formulation and crystallization. However, complications may occur in solubility 
measurements, because formation of aggregates or micelles in the solution can 
cause shifts in solubility which are related to shifts in pKa value. Therefore, in order to 
develop a more advanced prediction tool, new procedures should be developed to 
allow the determination of solubility in different solvent systems precisely. In 
conclusion, the generation of high quality data containing useful information is 
regarded as the crucial step in future model development. Today’s rapid advances in 
fully automated or robot-driven measurement systems as well as in high-speed and 
high-precision measurement technologies offer a promising perspective on the future 
of solubility models. 
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6 ABBREVIATIONS 
% C The percentage of aliphatic carbon in a molecule 
% aromatic atom The percentage of aromatic atoms in a molecule 
% NO The percentage of the sum of nitrogen and oxygen atoms in a 
molecule 
A Amphiphilic moment 
ApKa Acid pKa 
BpKa Base pKa 
CP Critical packing and defined as volume 
(hydrophobic)/[surface(hydrophilic)*length hydrophobic] 
d0  The “thickness” of the structure and defined as the root mean 
square deviation of the atom positions from the plane defined by 
the maximum and medium principal axes 
d1  The “width” of the structure and defined as d0 but for maximum 
and minimum axes 
d2  The “length” of the structure and defined as d0 but for the 
medium and minimum axes 
Emin1-3 The interaction energy between water and molecule at 3 best 
local minima 
GC Group Contribution 
HL1-2  Hydrophilic-lipophilic balance, which is defined as ratio of 
hydrophilic (-3, -4 kcal/mol)/lipophilic (-0.6, -0.8 kcal/mol) 
Abbreviations 
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MLR Multiple linear regression 
MP Melting point 
NN Neutral network 
Ovality  Defined as total surface area/surface area of a shere with 
volume equal to the total volume. This quantity must be larger 
than or equal to one 
PCA Principal component analysis 
PLS Projection to latent structure 
Rmse Root mean square error of the fit for observations in the data set 
Rg Radius of gyration, which is defined as root mean square 
distance of the atoms from the centroid 
S Solubility 
S0 The molarity of the unionized molecular species 
Log1/S0 The logarithmic transformed form of S0 
V Molecular volume 
VIP  Variable Influence on Projection 
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8 APPENDIX 
Nr. Name 
Connection 
Environment 
SMART bi 
Coeff 
(ClogP) 
Fragment 
contribution 
to log1/S0 
Frag1 Tertiary Amine AZZ AN(Z)Z -0.505804 -2.2 -0.78789 
Frag2 Tertiary Amine AAa A[N&X3](A)a 0.246447 -1.12 0.102841 
Frag3 Tertiary Amine AAA AN(A)A 0.112752 -2.37 -0.19113 
Frag4 Tertiary Amine AAZ AN(A)Z 0.03326 -1.98 -0.22062 
Frag5 Secondary amine AA A[NH]A 0.283721 -1.77 0.056772 
Frag6 Secondary amine Aa A[NH]a -0.0704758 -1.03 -0.20254 
Frag7 Secondary amine aa a[NH]a 0.0130401 -0.09 0.0015 
Frag8 Secondary amine AZ A[NH]Z 0.320647 -1.69 0.103955 
Frag9 Secondary amine Za [NH](Z)a -0.0950652 -1.15 -0.24252 
Frag10 Secondary amine ZZ [NH](Z)Z -0.0924969 -2.1 -0.36176 
Frag11 Primary Amine A A[NH2] 0.88698 -1.54 0.689521 
Frag12 Primary Amine Z [NH2]Z 0.800753 -1.35 0.627656 
Frag13 Primary Amine a a[NH2] -0.293951 -1 -0.42217 
Frag14 Acid Hydrazide-NH aa a[NH][NH]C(a)=O -0.21722 -2.3 -0.51213 
Frag15 Aromatic Amide aa a[nH]c(a)=O -0.148826 -2 -0.40527 
Frag16 Acid Imide Aza AN(C(Z)=O)C(a)=O -1.05145 -1.72 -1.27199 
Frag17 Amide AAA AN(A)C(A)=O -0.568526 -3.19 -0.97755 
Frag18 Amide AAa AN(A)C(a)=O -0.328139 -2.82 -0.68972 
Frag19 Amide AaA AN(a)C(A)=O -0.495233 -1.4 -0.67474 
  
Frag20 Amide aaa aN(a)C(a)=O -0.0949459 -0.33 -0.13726 
Frag21 Amide Aaa AN(a)C(a)=O 0.0412647 -2.09 -0.22672 
Frag22 Amide AaZ AN(a)C(Z)=O -0.459037 -2.12 -0.73086 
Frag23 Amide AAZ AN(A)C(Z)=O -0.860587 -2.99 -1.24396 
Frag24 Amide AZA AN(Z)C(A)=O -0.105184 -2.99 -0.48856 
Frag25 Amide AZa AN(Z)C(a)=O -0.3433 -2.2 -0.62538 
Frag26 Amide AZZ AN(Z)C(Z)=O -0.533844 -2.87 -0.90184 
Frag27 Formylamine AA AN(A)[CH]=O -0.103085 -2.67 -0.44543 
Frag28 NH-Amide AA A[NH]C(A)=O -0.260609 -2.71 -0.60809 
Frag29 NH-Amide Aa A[NH]C(a)=O -0.148322 -1.81 -0.3804 
Frag30 NH-Amide aA a[NH]C(A)=O -0.0877811 -1.51 -0.28139 
Frag31 NH-Amide aa a[NH]C(a)=O 0.0820121 -1.06 -0.0539 
Frag32 NH-Amide AV A[NH]C(V)=O -0.416968 -2.26 -0.70675 
Frag33 NH-Amide AZ A[NH]C(Z)=O -0.414681 -2.51 -0.73651 
Frag34 NH-Amide aZ a[NH]C(Z)=O -0.124235 -1.54 -0.32169 
Frag35 NH-Amide aV a[NH]C(V)=O -0.530449 -1.3 -0.69714 
Frag36 NH-Amide ZA [NH](Z)C(A)=O -0.58768 -2.25 -0.87618 
Frag37 NH-Amide Za [NH](Z)C(a)=O -0.0663947 -1.41 -0.24718 
Frag38 Formamine-NH a a[NH][CH]=O 0.0694213 -0.75 -0.02674 
Frag39 Urea (tetrasub) AAAA AN(A)C(=O)N(A)A -0.598173 -3.01 -0.98412 
Frag40 1,1,3-Urea Aaa A[NH]C(=O)N(a)a -0.085475 -2.16 -0.36243 
Frag41 1,1,3-Urea aAA a[NH]C(=O)N(A)A -0.282532 -2.77 -0.6377 
Frag42 1,1,3-Urea aAZ a[NH]C(=O)N(A)Z -0.492871 -2.09 -0.76085 
Frag43 N,N' Urea Aa A[NH]C(=O)[NH]a -0.137129 -1.57 -0.33843 
Frag44 N,N' Urea Za [NH](Z)C(=O)[NH]a 0.298589 -1.37 0.122928 
  
Frag45 NH-Urea a a[NH]C([NH2])=O -0.374615 -1.07 -0.51181 
Frag46 NH-Carbamate aA a[NH]C(=O)OA 0.288844 -1.06 0.152931 
Frag47 NH-Carbamate aZ a[NH]C(=O)OZ 1.01701 -1.06 0.881097 
Frag48 NH2-Amide a aC([NH2])=O 0.0208799 -1.26 -0.14068 
Frag49 NH2-Amide A AC([NH2])=O -0.411489 -1.99 -0.66665 
Frag50 NH2-Amide Z C(Z)([NH2])=O -0.131347 -1.99 -0.3865 
Frag51 Thioamide-NH aA a[NH]C(A)=S -0.420511 -0.96 -0.5436 
Frag52 Thioamide-NH2 A AC([NH2])=S 0.0493423 -1.13 -0.09555 
Frag53 Ester AA AOC(A)=O -0.275125 -1.45 -0.46104 
Frag54 Ester Aa AOC(a)=O -0.203746 -0.56 -0.27555 
Frag55 Ester AY AOC(Y)=O -0.086602 -0.96 -0.20969 
Frag56 Ester AZ AOC(Z)=O -0.124924 -1.38 -0.30187 
Frag57 Ester Za O(Z)C(a)=O -1.40291 -0.3 -1.44138 
Frag58 Carboxy (ZW -) A AC([OH])=O 0.509152 -1.07 0.371957 
Frag59 Carboxy (ZW -) a aC([OH])=O 1.08236 -0.03 1.078513 
Frag60 Carboxy Z C(Z)([OH])=O -0.295626 -1.03 -0.42769 
Frag61 Carbonyl Aa AC(a)=O 0.104273 -1.09 -0.03549 
Frag62 Carbonyl aa aC(a)=O -0.0367111 -0.53 -0.10467 
Frag63 Carbonyl AA AC(A)=O -0.61826 -1.84 -0.85418 
Frag64 Aldehyde a a[CH]=O 0.00267908 -0.42 -0.05117 
Frag65 Ether AA AOA -0.12718 -1.82 -0.36054 
Frag66 Ether Aa AOa -0.00697339 -0.61 -0.08519 
Frag67 Ether aa aOa 0.167299 0.53 0.235256 
Frag68 Ether AY AOY -0.0610615 -1.3 -0.22775 
Frag69 Ether AZ AOZ 0.242133 -1.28 0.078011 
  
Frag70 Ether aZ aOZ 0.153457 -0.41 0.100887 
Frag71 Alcohol or Hydroxy A A[OH] -0.372527 -1.64 -0.58281 
Frag72 Alcohol or Hydroxy a a[OH] -0.331856 -0.44 -0.38827 
Frag73 Alcohol or Hydroxy Z [OH]Z 0.00490034 -1.34 -0.16691 
Frag74 Sulfide AA A[S&X2]A 0.415272 -0.7 0.325518 
Frag75 Sulfide Aa A[S&X2]a -0.093221 0.03 -0.08937 
Frag76 Sulfide aa a[S&X2]a 0.14817 0.77 0.246899 
Frag77 Sulfide AZ A[S&X2]Z -0.613268 -0.35 -0.65815 
Frag78 Sulfide VV V[S&X2]V -0.416968 0.18 -0.39389 
Frag79 Sulfide Za [S&X2](Z)a 0.591607 0.03 0.595454 
Frag80 Azo A AN=[N+]=[N-] -0.479841 0.62 -0.40034 
Frag81 Nitro a a[N+](=O)[O-] 0.00594268 -0.03 0.002096 
Frag82 Nitrile a aC#N 0.255116 -0.34 0.211521 
Frag83 Nitrile A AC#N -0.0841117 -1.27 -0.24695 
Frag84 Nitrile Z C(Z)#N 0.742307 -0.88 0.629473 
Frag85 Fluoride A AF -0.0522532 -0.38 -0.10098 
Frag86 Fluoride a aF 0.05092 0.37 0.098361 
Frag87 Fluoride Z FZ 0.019207 -0.18 -0.00387 
Frag88 Chloride a aCl 0.0639783 0.94 0.184505 
Frag89 Chloride Z ClZ 0.304997 0.26 0.338334 
Frag90 Bromide a aBr 0.364067 1.09 0.503827 
Frag91 Iodide a aI 0.0205602 1.35 0.193657 
Frag92 Sulfoxide AA A[S&X3](A)=O -0.5968 -3.01 -0.98274 
Frag93 Sulfonyl AA AS(A)(=O)=O 0.0359061 -3.01 -0.35004 
Frag94 Sulfonyl Aa AS(a)(=O)=O 0.633814 -2.17 0.355577 
  
Frag95 Sulfonamide AAa AN(A)S(a)(=O)=O -0.179356 -2.09 -0.44734 
Frag96 Sulfonamide Aaa AN(a)S(a)(=O)=O 0.122288 -1.67 -0.09184 
Frag97 Sulfonamide AAA AN(A)S(A)(=O)=O -0.388641 -1.37 -0.5643 
Frag98 Sulfonamide AAZ AN(A)S(Z)(=O)=O -0.295066 -2.76 -0.64895 
Frag99 Sulfonamide AZa AN(Z)S(a)(=O)=O -0.362315 -1.89 -0.60465 
Frag100 NH-Sulfonamide Aa A[NH]S(a)(=O)=O -0.150474 -1.75 -0.37486 
Frag101 NH-Sulfonamide aA a[NH]S(A)(=O)=O -2.31194 -1.72 -2.53248 
Frag102 NH-Sulfonamide aa a[NH]S(a)(=O)=O -0.213922 -1.13 -0.35881 
Frag103 NH-Sulfonamide aZ a[NH]S(Z)(=O)=O -0.228931 -1.6 -0.43408 
Frag104 NH-Sulfonamide AA A[NH]S(A)(=O)=O -1.21692 -2.5 -1.53747 
Frag105 NH-Sulfonamide AZ A[NH]S(Z)(=O)=O -0.181414 -2.42 -0.49171 
Frag106 NH-Sulfonamide Za [NH](Z)S(a)(=O)=O -0.542045 -1.55 -0.74079 
Frag107 NH2-Sulfonamide a aS([NH2])(=O)=O 0.035859 -1.61 -0.17058 
Frag108 tetrasubst. Sulfamide AAAA AN(A)S(=O)(=O)N(A)A -0.287803 -4.05 -0.80709 
Frag109 Sulfondiamide, trisubs. AAA A[NH]S(=O)(=O)N(A)A -0.761375 -3.4 -1.19732 
Frag110 Sulfondiamide,trisubs aAA a[NH]S(=O)(=O)N(A)A 0.428803 -2.043 0.16685 
Frag111 Sulfondiamide,trisubs ZAA [NH](Z)S(=O)(=O)N(A)A -0.0114224 -1.545 -0.20952 
Frag112 Thiadiazoledioxide AA A[NH]S(=O)(=O)[NH]A -0.942546 -1.775 -1.17014 
Frag113 N-carboxysulfonamide aa aC(=O)[NH]S(a)(=O)=O -1.69519 -0.97 -1.81956 
Frag114 sulfonylurea,N(disubst-
amino) 
AAa AN(A)[NH]C(=O)[NH]S(a)(=O)=O 0.0325044 -4.34 -0.52397 
Frag115 1-Sulfonyl-3-Urea Aa A[NH]C(=O)[NH]S(a)(=O)=O -0.519879 -2.26 -0.80966 
Frag116 FragA AA A[NH]S(=O)(=O)[NH]C(=O)OA -1.24472 -1.745 -1.46846 
Frag117 FragB AAa AN(A)C=NS(a)(=O)=O -0.318364 -1.745 -0.54211 
Frag118 FragC Aaaa An(a)c(=O)n(a)S(a)(=O)(=O) -1.04836 -2.728 -1.39814 
Frag119 FragD Zaaa n(Z)(a)c(=O)n(a)S(a)(=O)(=O) 0.774524 -2.728 0.42474 
  
Frag120 FragE aaa [nH](a)c(=O)n(a)S(a)(=O)(=O) -0.154406 -2.424 -0.46521 
Frag121 Thiophosporothioate AAA AOP(=S)(OA)SA -0.051248 0.1 -0.03843 
Frag122 FragF A AOP([OH])([OH])=O 1.15179 -2.174 0.87304 
Frag123 FragG AAa A[N+](A)(a)[O-] -2.09328 -1.349 -2.26625 
Frag124 cyanoguanidyl #1 aAA a[NH]C(=NC#N)N(A)A -1.56706 -1.104 -1.70861 
Frag125 Oxanilic ester aA a[NH]C(=O)C(=O)OA 0.249812 -1.72 0.029274 
Frag126 Amidine a aC([NH2])=[NH] 0.46317 -1.27 0.300331 
Frag127 FragH aa aC([NH2])=NC(a)=O 0.537292 -1.137 0.391506 
Frag128 FragI a aC([NH2])=NO -0.0988768 -0.891 -0.21312 
Frag129 Dicarbonylhydrazine (sym) aa aC(=O)[NH][NH]C(a)=O -0.392074 -1.49 -0.58312 
Frag130 Acid Hydrazide-NH2 A AC(=O)[NH][NH2] 0.212569 -2.5 -0.10798 
Frag131 N,N-carboxamide,alpha-
keto 
AZA AN(Z)C(=O)C(A)=O 0.046828 -3.105 -0.3513 
Frag132 Formocarboxamide Aa AN[CH]=O)C(a)=O 0.18389 -1.43 0.000535 
Frag133 Acid Imide Aaa AN(C(a)=O)C(a)=O 0.00251297 -1.05 -0.13212 
Frag134 Tertiary Imine Aaa AN=C(a)a -0.28748 -1.65 -0.49904 
Frag135 Carbamate, N, N AAA AOC(=O)N(A)A -0.00739098 -1.95 -0.25742 
Frag136 N-carboxyguanidyl Aa AOC(=O)N=C(a)[NH2] 0.357515 -1.5 0.165185 
Frag137 Carbonate AA AOC(=O)OA 0.0425553 -1.93 -0.20491 
Frag138 Iminoxy Aa AON=Ca 0.0416457 -0.6 -0.03529 
Frag139 FragJ aa a[n+](a)[O-] -0.740466 -1.745 -0.96421 
Frag140 1-Pyrrole Aaa An(a)a -0.0874169 -1.09 -0.22718 
Frag141 1-Pyrrole aaa an(a)a -0.167806 -0.56 -0.23961 
Frag142 1-Pyrrole Zaa n(Z)(a)a -0.181305 -0.89 -0.29542 
Frag143 Ring amide, N-subst. aaa an(a)c(a)=O -0.754877 -2.35 -1.05619 
Frag144 Ring amide, N-subst. aZa an(Z)c(a)=O -0.525923 -2.39 -0.83237 
  
Frag145 Arom.1-(3H)Diazo-2,4-
dioxo Zaa n(Z)(a)c(=O)[nH]c(a)=O -1.09721 
-2.79 -1.45494 
Frag146 disubst.pyrimidin-dione Zaaa n(Z)(a)c(=O)n(a)c(a)=O -0.0664098 -1.91 -0.31131 
Frag147 FragK AAaa AN(A)n(a)c(a)=O -0.0620699 -3.297 -0.48481 
Frag148 1-amino-2-pyridone aa an([NH2])c(a)=O -0.842206 -1.6 -1.04736 
Frag149 Tetrazolyl Ya n1(Y)annn1 0.174292 -1.77 -0.05266 
Frag150 2_3_4_trisubst_urazole ZZa n1(Z)n(Z)c(=O)n(a)c1=O -0.708604 -2.207 -0.99159 
Frag151 2-tetrazolyl Aa An1nann1 -0.651707 -1.65 -0.86327 
Frag152 2-tetrazolyl Za n1(Z)nann1 -0.0943726 -1.65 -0.30594 
Frag153 2-pyrimidinone aZa a[n&X2]c(=O)n(Z)a 0.643812 -3.12 0.243766 
Frag154 Triazole aaa annn(a)a 0.293345 -1.25 0.13307 
Frag155 Isoxazolyl aa a[n&X2]oa -0.237556 -0.95 -0.35937 
Frag156 Isothiazole #1 aa a[n&X2]sa -0.342363 -0.2 -0.36801 
Frag157 134triazinone a O=c1[nH]an[nH]1 1.36702 -1.01 1.237518 
Frag158 Aromatic Diazo (TYPE 2) aa a[n&X2][n&X2]a -0.483229 -2.16 -0.76018 
Frag159 Diazole-N-subst. aaa a[n&X2]n(a)a -0.0462078 -1.1 -0.18725 
Frag160 Diazole-N-subst. aYa a[n&X2]n(Y)a -0.0872313 -1 -0.21545 
Frag161 Diazole-N-subst. aAa a[n&X2]n(A)a -0.289211 -1.69 -0.5059 
Frag162 Diazole-N-subst. aZa a[n&X2]n(Z)a -0.363835 -1.69 -0.58053 
Frag163 Aromatic NH aa a[nH]a -0.0163266 -0.68 -0.10352 
Frag164 Aromatic oxygen aa a[o&X2]a 0.108018 -0.11 0.093914 
Frag165 Thiophenyl aa a[s&X2]a -0.0664319 0.36 -0.02027 
Frag166 Aromatic_nitrogen_TYPE2 aa a[n&X2]a 0.031963 -1.14 -0.11421 
Frag167 Aliphatic carbon  [C;!$(*=,#[!#6])] 0.0163697 0.195 0.041373 
Frag168 Aromatic carbon  [c;!$(*=,#[!#6])] 0.0435754 0.13 0.060244 
Frag169 NH-Amide ZZ Z[NH]C(Z)=O    
  
Frag170 Tertiary Imine aAa aN=C(A)a    
CorrFrag1 Aliphatic ring   0.0503823   
CorrFrag2 Trifluoromethyl  C(F)(F)F 0.0649662   
CorrFrag3 
N
S
N
H
S
O
O
 
a aS(=O)(=O)[NH]c1sc2ccccc2n1 1.24005   
CorrFrag4 S
 
 s1ccc2ccccc12 0.528395   
Table 35:  Fitting 170 fragments and 4 correction factors to the solubility data of 2473 drug-like compounds in 81 congeneric series. bi is the coefficient 
of the fragments described in the equation of 81803.3**log*12822.0/1
81
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fragments Z[NH]C(Z)=O and aN=C(A)a are major components of scaffolds, thus, their fragmental constants were statistically not well 
validated. 
Appendix 
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Nr. ci Nr. ci Nr. ci Nr. ci 
Scaffold1 -0.82929 Scaffold21 -0.92209 Scaffold41 -0.36708 Scaffold61 0.061132 
Scaffold2 -0.36232 Scaffold22 -0.28748 Scaffold42 0.85059 Scaffold62 -0.37454 
Scaffold3 -0.88836 Scaffold23 0.016066 Scaffold43 -0.0925 Scaffold63 0.117622 
Scaffold4 -0.97198 Scaffold24 -0.38336 Scaffold44 -0.61775 Scaffold64 -0.64903 
Scaffold5 -0.22905 Scaffold25 0.977961 Scaffold45 0.138562 Scaffold65 0.170775 
Scaffold6 -0.01408 Scaffold26 -0.43312 Scaffold46 -0.946 Scaffold66 0.041265 
Scaffold7 -0.39203 Scaffold27 -0.17257 Scaffold47 -1.06197 Scaffold67 -0.36912 
Scaffold8 -0.24554 Scaffold28 -0.3399 Scaffold48 -0.18632 Scaffold68 -0.52412 
Scaffold9 -0.21366 Scaffold29 -1.97686 Scaffold49 -0.18391 Scaffold69 0.506033 
Scaffold10 0.381965 Scaffold30 -0.33184 Scaffold50 0.192332 Scaffold70 1.08843 
Scaffold11 -0.26606 Scaffold31 -0.38843 Scaffold51 0.360716 Scaffold71 0.230182 
Scaffold12 0.032504 Scaffold32 -0.45904 Scaffold52 0.833598 Scaffold72 -0.17462 
Scaffold13 -0.51988 Scaffold33 -0.06644 Scaffold53 1.04617 Scaffold73 -0.07553 
Scaffold14 -0.80882 Scaffold34 -0.0866 Scaffold54 -0.15332 Scaffold74 2.09032 
Scaffold15 -3.35E -05 Scaffold35 0.521279 Scaffold55 -0.2185 Scaffold75 -2.2763 
Scaffold16 0.430987 Scaffold36 1.31949 Scaffold56 -0.22962 Scaffold76 0.316835 
Scaffold17 -0.17408 Scaffold37 -0.11513 Scaffold57 -0.08548 Scaffold77 -0.26243 
Scaffold18 -0.22399 Scaffold38 -0.30322 Scaffold58 -0.69876 Scaffold78 -0.10436 
Scaffold19 -0.3978 Scaffold39 0.058895 Scaffold59 0.143422 Scaffold79 -0.44006 
Scaffold20 -0.06641 Scaffold40 -0.21242 Scaffold60 -0.95461 Scaffold80 0.185193 
      Scaffold81 -0.21854 
Table 36:  Fitting 170 fragments and 4 correction factors to the solubility data of 2473 drug-like 
compounds in 81 congeneric series. ci is the coefficient of the congeneric series indices 
described in the equation of 81803.3**log*12822.0/1
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Table 37:  Fragments are scaled according to its contribution to the LogS0. Solubility increases with higher LogS0 value. 
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Table 38:  Fragments are scaled according to its contribution to the LogS0. Solubility increases with higher LogS0 value. 
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